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4ABSTRACT
Cancer is one of the most common reasons for death in dogs, cats and humans. 
New therapeutic modalities are necessary to improve disease outcome. One 
promising approach is oncolytic virotherapy. Until now, the only oncolytic 
virus evaluated in a clinical trial in veterinary medicine has been canine 
oncolytic adenovirus, but a clinical trial has been started with oncolytic 
vaccinia virus (VV) in pet dogs. In cats, oncolytic viruses have not been 
evaluated in clinical settings. Tumour treatment in dogs and cats could also 
serve as a model for human cancer therapy. 
The purpose of the thesis was to evaluate preclinically whether genetically 
modified oncolytic VV and Semliki Forest virus (SFV) could offer a new 
treatment modality for dogs and cats. Oncolytic VV was rendered tumour 
selective by a dual ablation of vaccinia growth factor and thymidine kinase,
making it more cancer-specific than previously used VVs in veterinary 
research. To further increase the efficacy of the VV, an immunostimulatory 
gene, CD40L, was added to the virus backbone. Avirulent SFV A7(74) has a 
natural trophism for cancer cells and was not genetically manipulated.
Both viruses infected and killed tested cancer cell lines, and VV also 
infected most of the primary surgical tumour tissues tested. In the nude mouse 
xenograft model, double deleted VV (vvdd) significantly reduced tumour 
growth. Interestingly, when in intact monolayers, SCCF1 cells were not killed 
by VV, but secreted infectious, morphologically abnormal virions. One dog 
experienced a possible seizure after VV administration, but no other serious 
adverse events occurred. Vaccinia DNA declined quickly in the blood after 
virus administration, but was still detectable one week later by qPCR. Only 
samples taken directly after the VV infusion contained infectious virus, which 
was not found in any other blood, saliva, urine or faecal samples. Necropsies 
did not reveal any pathological changes associated with virus administrations. 
In conclusion, our results show that oncolytic VV and SFV can infect and 
kill tested canine cancer cell lines, and that VV has antitumoral activity in the 
mouse xenograft model and it can infect fresh tumour biopsies. In addition,
intravenous administration of the viruses did not induce life-threatening
adverse events in healthy dogs. These agents thus warrant further evaluation 
in veterinary medicine.
5TIIVISTELMÄ
Syöpä on yksi yleisimmistä koirien, kissojen ja ihmisten kuolinsyistä, minkä 
vuoksi uusia hoitomuotoja tarvitaan parantamaan hoitotuloksia. Onkolyytti-
set virukset ovat yksi lupaava syövän hoitomuoto. Eläinlääketieteessä ainoas-
taan onkolyyttistä koirien adenovirusta on käytetty koirien syövän hoidossa, 
mutta kliininen hoitokoe on meneillään myös onkolyyttisellä vaccinia viruk-
sella. Kissojen syöpien hoidossa ei ole vielä käytetty onkolyyttisiä viruksia.
Koirien ja kissojen kasvaimet voivat toimia myös mallina ihmisten syöpien 
hoitoon.
Tämän tutkimuksen tarkoituksena oli arvioida prekliinisesti geneettisesti 
muunnellun onkolyyttisen vaccinia viruksen ja Semliki Forest viruksen (SFV) 
tehoa koirien ja kissojen syöpien hoidossa.
Tutkimuksessa käytettävästä vaccinia viruksesta oli poistettu vaccinian 
kasvutekijä- ja tymidiinikinaasigeeni, jolloin virus on syöpäspesifisempi kuin 
aikaisemmat eläinlääketieteellisissä tutkimuksissa käytetyt vaccinia virukset. 
Lisäksi vaccinia virukseen on lisätty immuunipuolutusta parantava CD40L-
geeni. Avirulentti SFV A7/(74) puolestaan hakeutuu luonnostaan kasvainku-
dokseen ja lisääntyy siellä.
Sekä vaccinia virus että SFV kykenivät tappamaan syöpäsoluja. Vaccinia 
virus infektoi useimmat koirien kasvainkudokset sekä hidasti merkittävästi 
hiirille aiheutettujen syöpien kasvua. Vaccinia viruksen lisääntyminen kissan 
levyepiteelikarsinoomasoluissa oli poikkevaa, koska syntyneet virukset olivat
morfologialtaan epänormaaleja, mutta kuitenkin infektiokykyisiä. Virusten 
antaminen ei aiheuttanut merkittäviä haittavaikutuksia koirille, mutta yhdellä 
koiralla epäiltiin vaccinia viruksen aiheuttamaan epileptiformista kohtausta. 
Vaccinia viruksen DNA:n määrä laski nopeasti veressä infuusion jälkeen, 
mutta DNA:ta todettiin veressä vielä viikon päästä. Infektiivistä vaccinia 
virusta todettiin ainoastaan verinäytteissä, jotka kerättiin välittömästi 
virusinfuusion jälkeen. Virtsa-, sylki- ja ulostenäytteissä viruksia ei todettu.
Tutkimustulostemme perusteella onkolyttinen vaccinia virus ja SFV infek-
toivat ja tappoivat testattuja koiran kasvainsolulinjoja ja lisäksi vaccinia virus 
hidasti syövän kasvua hiirimallissa ja infektoi potilaskoirista kerättyjä kas-
vaimia. Kumpikaan virus ei aiheuttanut henkeäuhkaavia haittavaikutuksia 
terveillä koirilla. Löydöstemme perusteella kumpaakin virusta kannattaa 
tutkia lisää koirien syöpien hoidossa.
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ABBREVIATIONS
A549 human lung adenocarcinoma epithelial cell line
A7(74) avirulent Semliki Forest virus strain
Abrams canine osteosarcoma cell line
ACE-1 canine prostatic carcinoma cell line
Ad5/3-hTERT adenovirus type 5/3 expressing human telomerase reverse 
transcriptase
Ad5/3-hTERT-CD40L
adenovirus type 5/3 expressing human telomerase reverse 
transcriptase and CD40L 
AdCD40L adenovirus expressing CD40L
ALP alkaline phosphatase
ALT alanine animotransferase
ANOVA analysis of variance
B16-OVA murine melanoma cell line expressing ovalbumin
Bcl-2 B cell lymphoma 2
BHK-21 baby hamster kidney cell line
BDIX Berlin Duckrey IX inbret rat strain
BT4C glioma induced by giving a single transplacental 
administration of N-ethyl-N-nitrosourea to pregnant BDIX 
rats
CAV canine adenovirus
CD cytosine deaminase
CDC Centers for Disease Control and Prevention
CD40L cluster of differentiation 40 ligand
CDRS cytosine deaminase and somatostatin receptor gene
CEV cell-associated extracellular enveloped virus
CNS central nervous system
CO2 carbon dioxide
CPE cytopathic effect
CPXV cowpox virus
CT-2A mouse astrocytoma cell line
D17 canine osteosarcoma cell line
DAB 3,3’-diaminobenzidine
DC dendritic cell
DMEM Dulbecco’s modified Eagle’s medium
DNA deoxyribonucleic acid
DT09/06 feline mammary carcinoma cell line
EDTA ethylenediaminetetraacetic acid
EEV extracellular enveloped virus
EGFP enhanced green fluorescent protein
EGRF epidermal growth factor pathway
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EM electron microscopy
EV extracellular virus
FCS foetal calf serum
GAG glycosaminoglycans
GFP green fluorescent protein
GLAF-1 anti-VEGF single-chain antibody 1
GLAF-2 anti-VEGF single-chain antibody 2
GLONC1 Genelux Corporation oncolytic virus GLV-1h68
GLV-1h68 oncolytic vaccinia virus derived from the vaccinia virus 
LIVP strain expressing luciferase, green fluorescent 
protein, ?-????????????????????-glucuronidase
GLV-1h109 oncolytic vaccinia virus derived from GLV-1h68 expressing 
GLAF-1
GLV-5b451 oncolytic vaccinia virus derived from LIVP 6.1.1 expressing 
GLAF-2
GM growth medium
GM-CSF granulocyte-monocyte colony-stimulating factor
GMP good manufacturing practices
GusA beta-glucuronidase
HA J7R hemagglutinin J7R
hCD40L human CD40 ligand
HE haematoxylin and eosin
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid N-(2-
hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
IEV intracellular enveloped virus
IFN interferon
IgG immunoglobulin G
IgM immunoglobulin M
IL interleukin
IM immature virus
IMV intracellular mature virus
IVN immature virion with nucleoids
ITR inverted terminal repeat
JX-549 thymidine kinase gene-inactivated oncolytic Wyeth strain 
vaccinia virus expressing granulocyte-macrophage colony-
stimulating factor and lac-Z by Jennerex
JX-929 double deleted oncolytic Western Reserve strain vaccinia 
virus expressing green fluorescent protein by Jennerex
K2 dipotassium
kb kilobase pair
KPT potassium phosphotungstate
LacZ ?-galactosidase gene
LIVP1.1.1 oncolytic vaccinia virus derived from Lister strain, Institute of 
Viral Preparations, Moscow, Russia
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LIVP6.1.1 oncolytic vaccinia virus derived from Lister strain, Institute of 
Viral Preparations, Moscow, Russia
MDCK Madin-Darby canine kidney cell line
MHC major histocompatibility complex
MOI multiplicity of infection
mRNA messenger RNA
MTD maximum tolerated dose
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium
MV mature virus
NAb neutralizing antibody
NaCl sodium chloride
NIS sodium iodide symporter gene
NR-417 antibody for intracellular mature vaccinia virus
OC-CAVE1 conditionally replicating canine adenovirus type 2
ONYX-015 oncolytic adenovirus replicating in and killing cells with p53 
mutations by Onyx Pharmaceuticals
OPV orthopoxvirus
OVA ovalbumin
P-S penicillin-streptomycin
PBMC peripheral blood mononuclear cell
PBS phosphate-buffered solution
PCR polymerase chain reaction
p.i. post-infection
pfu plaque-forming unit
qPCR quantitative polymerase chain reaction
pRb retinoblastoma protein
RGD arginylglycylaspartic acid
RNA ribonucleic acid
SCCF1 feline squamous carcinoma cell line
SCID severe combined immunodeficiency 
SFV Semliki Forest virus
SR somatostatin receptor
ST-246 tecovirimat, an antiviral agent for orthopoxvirus infections
T-VEC oncolytic herpes virus expressing granulocyte macrophage 
colony-stimulating factor
TCID50 tissue culture infectious dose killing 50% of the cells
TEM transmission electron microscopy
TK thymine kinase
TNF tumour necrosis factor
Treg T regulatory cell
U2OS human osteosarcoma cell line
V-VET1 LIVP6.6.1
VA7-EGFP replication-competent avirulent Semliki Forest virus
expressing enhanced green fluorescent protein
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VCOG-CTCAE Veterinary cooperative oncology group - Common 
terminology criteria for adverse events
VEGF vascular endothelial growth factor
VGF vaccinia growth factor
VIG vaccinia immune globulin
vp virus particle
VSV vesicular stomatitis virus
VV vaccinia virus
vvdd double-deleted vaccinia virus with TK and VGF deletions
vvdd-hCD40L-tdTomato
double-deleted vaccinia virus expressing human CD40L and 
tdTomato
vvdd-luc double-deleted vaccinia virus expressing Firefly luciferase
vvdd-tdTomato double-deleted vaccinia virus expressing tdTomato
WV wrapped virus
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1 INTRODUCTION
As in humans, cancer is one of the most common reasons for death in dogs and 
cats. Surgery, chemotherapy and radiation therapy are the most prevailing 
treatments in veterinary oncology (Withrow et al. 2013), but in parallel with 
the human situation new approaches are needed, especially for advanced 
metastatic solid tumours, which are often incurable with traditional therapies. 
In addition, particularly in pets, maintaining the quality of life is very 
important and only minimal adverse events are accepted (Withrow et al. 
2013).
Dogs and cats with spontaneous cancer serve as a good model for human 
cancers (Vail & MacEwen 2000, Hemminki et al. 2003, Ranieri et al. 2013, 
Wypij 2013, Laborda et al. 2014). Dogs share the same environment with their 
owners, their immune system is intact, their size is close to humans relative to 
laboratory rodents and cancer progression is spontaneous. These in addition 
to ethical reasons are key advantages over laboratory rodents. Like cancer in 
human patients but not in rodent models, cancer arising in dogs develops over 
several years, resulting in similar complexity, clonality and immune 
suppression as seen in man. The biological behaviour also has many 
similarities, including metastatic patterns, relapse and treatment resistance. 
In addition, the same cancer-associated genes and histological features have 
been found in both species (Vail & MacEwen 2000, Wang et al. 2013).
Oncolytic virotherapy, where replication-competent viruses are armed 
with immunostimulatory transgenes, is a promising new treatment approach 
(Buller et al. 1988, McCart et al. 2001, Cerullo et al. 2012b, Elsedawy & Russell 
2013, Gentschev et al. 2014). Before directly killing cancer cells, 
immunostimulatory genes are expressed by infected cells to awaken the host 
immune system, which is suppressed by the tumour microenvironment in 
progressing clinically evident tumours (Elsedawy & Russell 2013). Then, 
infected tumour cells are killed by oncolysis, releasing a broad variety of 
tumour antigens into the environment for the adaptive immune system to 
sample (Elsedawy & Russell 2013).
In 2006, the first oncolytic virus, oncolytic adenovirus ONYX-015, was 
approved on the market in China (Woller et al. 2014). Although the treatment 
response has been modest, multiple clinical trials investigating oncolytic 
viruses in different cancer types in humans are ongoing (National Cancer 
Institute 2014). Also undergoing development is oncolytic herpes virus T-Vec 
expressing granulocyte macrophage colony-stimulating factor (GM-CSF), 
which has demonstrated durable responses and improved survival in patients 
with advanced melanoma (Woller et al. 2014). In addition, vaccinia virus (VV)
JX-594 has shown promise in early clinical trials and expresses the same 
transgene, GM-CSF, as T-Vec events (Mastrangelo et al. 1999, Park et al. 2008, 
Breitbach et al. 2011, Hwang et al. 2011, Heo et al. 2013). A clinical trial has 
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also been started in cancer-bearing dogs in the USA with an oncolytic VV called 
V-VET1 (Gentschev et al. 2013). However, the ultimate breakthrough with 
oncolytic viruses has yet to occur.
The aims of this thesis were to investigate whether genetically modified 
oncolytic vaccinia virus and Semliki Forest virus (SFV) would be efficient and 
safe oncolytic agents in preclinical evaluation for treatment of canine and 
feline otherwise incurable cancers. 
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2 REVIEW OF THE LITERATURE
2.1 VACCINIA VIRUS
Vaccinia virus (VV) is a typical Poxvirus belonging to Orthopoxvirus (OPV) 
genus, Poxviridae family and Chordopoxvirinae subfamily. Other well-known 
viruses in the same genus include variola virus and cowpox virus, which cause 
smallpox and cowpox, respectively. 
The origin of VV is uncertain, but it is has been used to eradicate smallpox 
worldwide. In the 1800 century, when smallpox was common in society, it was 
noticed that milkers did not get smallpox. Jenner found out that these 
individuals had already had a disease called cowpox and concluded that 
cowpox prevents smallpox infection (Fenner & World Health Organization 
1988). To prove his theory, Jenner inoculated cowpox in humans and was able 
to show that persons previously exposed to cowpox did not get smallpox. At 
the beginning of the 1900 century, Jenner isolated the virus from horses and 
started to use horsepox virus in smallpox vaccines. The smallpox vaccine based 
on horsepox virus was later used throughout Europe; however, during 
vaccination multiple different laboratory strains were developed (Fenner & 
World Health Organization 1988). The most commonly used strains are shown 
in Table 1.
Table 1 Vaccinia virus strains. Adapted from Guse et al. (2011).
Strain Background Characteristics
Copenhagen Northern European vaccine 
strain
Inherent tumour selectivity 
Used as smallpox vaccine but withdrawn 
due to adverse events
Lister European vaccine strain Inherent tumour selectivity
Extensive use during smallpox 
eradication
Modified Ankara Derived from Ankara strain 
through passage in avian 
cells
Does not replicate in mammalian cells 
Highly immunogenic: good vaccine
New York Vaccine strain derived from 
Copenhagen strain 
Does not replicate in mammalian cells 
Highly immunogenic: good vaccine
Tin Tan Chinese vaccine strain Used in China during smallpox 
eradication Oncolytic potential unknown
Wyeth /
New York City 
Board of Health
Northern American vaccine 
strain
Minimal inherent tumour selectivity 
Slow replication in mouse tissue 
Commonly used clinical strain
Western Reserve Laboratory strain derived 
from Wyeth through 
passage in mice brain
High tumour selectivity 
Strong oncolytic effect in mouse models
Minimal use in humans
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2.1.1 Biology of vaccinia virus
VV virion is a brick-shaped particle of approximately 360 x 270 x 250 nm and 
composed of approximately 75 proteins (Kroon et al. 2011). It has a single 
linear double-stranded DNA consisting of ca. 200 kilobase pairs (kb), and both 
ends have a hairpin loop. Genes in the centre encode conserved proteins vital 
for virus replication, whereas genes near the ends encode proteins associated 
with non-vital functions such as evading the host immune system and affecting 
virulence. Inverted terminal repeats are found at both ends of the genome. The 
genome of VV codes for more than 200 genes and can carry up to 25 kb of 
foreign transgenes.
VV replication happens in the cytoplasmic inclusions, where infecting 
virions are partly uncoated by cellular enzymes and then fully uncoated by 
viral enzymes released from the virion core. The replication cycle is divided 
into two parts controlled by either early or late gene products (Condit et al. 
2006).
The virion has three different infectious forms:  (1) mature virus (MV), (2) 
wrapped virus (WV) and (3) extracellular virus (EV) (Moss 2012). MV has a 
single lipid bilayer envelope and was previously called an intracellular mature 
virus (IMV) due to its intracellular location. WV has a double bilayer envelope 
and is located either intracellularly or extracellularly. Based on location, WV
was previously divided further into three forms: (1) intracellular enveloped 
virus (IEV), (2) extracellular enveloped virus (EEV) and (3) cell-associated 
extracellular enveloped virus (CEV) (Ward & Moss 2001). IMV is the most 
common type of VV and is released outside the cell during oncolysis, whereas 
CEV and EEV bud out from the intact host cell.
Infection starts when the virus enters the cell by fusion with the host cell 
membrane. This requires an entry-fusion complex, which is also necessary for 
cell-to-cell spread of EV and suggests that the outer envelope is lost before 
fusion. After entering the cytoplasm, the early stage of transcription begins, 
involving proteins associated with uncoating of the viral DNA, DNA 
replication and intermediate transactivation for transcription of intermediate 
mRNA. Early viral genes prevent host cell functions almost completely for 4-6
hours after infection, allowing effective transcription and viral replication, 
which begins 1-2 hours after infection. Intermediate mRNA encodes late 
transactivators and results in late mRNA synthesis and production of 
membrane and early transcription factor structural proteins, which are added 
to the new virion.
Development of the crescent-shaped membrane structure composed of 
lipid and viral proteins is the first step in VV morphogenesis. As the crescents 
surround core proteins and enlarge, they become spherical immature viruses 
(IMs), which contain the genomic DNA. An immature virus becomes an 
infectious MV when crescents join together and form a core and become brick-
shaped after proteolytic processes and disulphide bond formation 
(Satheshkumar et al. 2013). MVs are wrapped into two more membranes and
transported to cell surface where the outer membrane fuses with the plasma 
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membrane. Retained or reattached virus is called CEV, whereas released virus 
is EEV. The whole replication cycle takes approximately 12 hours. The 
replication cycle of VV is presented in Figure 1.
VV can infect multiple species, including humans, cattle, rodents, monkeys 
and horses (Kroon et al. 2011). In the laboratory setting, VV is commonly 
investigated in mice and rabbits (Kotwal & Abrahams 2004), but VV can also 
infect dog and cat cell lines (Gentschev et al. 2009, Gentschev et al. 2012, 
Adelfinger et al. 2014).
VV and other OPV infections induce both humoral and CD4+ and CD8+ T
cell response (Xu et al. 2004, Smith et al. 2013). Clearance of VV infection in 
an acute infection is suggested to occur mainly via virus-specific antibodies 
(Xu et al. 2004). In the antibody-depleted and gene knock-out mouse model, 
CD4+ T cells and major histocompatibility complex (MHC) class II-mediated 
immunity were crucial for VV clearance, whereas CD8+ T cell response 
determined how severe the VV infection was and how long the antibodies 
protected against a new OPV infection (Xu et al. 2004).
Replication cycle of vaccinia virus. Modified from Moss (2006) and McCart and 
Barlett (2009). GAGs, glycosaminoglycans; EEV, extracellular enveloped virus; IMV, intracellular 
enveloped virus (also called mature virus, MV); IV, immature virus; CEV, cell-associated 
enveloped virus. Wrapped virus (WV) includes IEV, EEV and CEV.
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While VV is more immunogenic than smallpox virus, like all poxviruses, VV 
also carries an arsenal of immune evasion functions (Smith et al. 2013). For 
example, VV expresses vaccinia complement protein, which blocks 
complement activation. In addition, EEV envelope expresses host complement 
control proteins making EEV less vulnerable to complement inactivation than 
IMV. VV also inhibits production, function and signal transduction of
interferon and pro-inflammatory cytokines such as tumour necrosis factor 
(TNF) and interleukin (IL) 1 and 18 (Smith et al. 2013). Further, VV can 
prevent chemokine expression or its action by producing chemokine-binding 
proteins and prevent apoptosis by producing anti-apoptotic Bcl-2-like 
proteins and inhibiting caspase-1 in apoptosis. VV also down-regulates MHC 
class I expression in infected cells to avoid cytotoxic T cells and modulates
natural killer cell function.
VV is very stable in the environment; infectious VV was recovered from a 
scab collected from a small pox vaccination site and saved at room 
temperature for 13 years (Wolff & Croon 1968). Also, infectious small pox virus 
was found in the household of a vaccinated person 10 days after he had left the 
house (Lederman et al. 2009). In addition, VV can remain infectious for 4 
months at +4°C in water (Essbauer et al. 2007), and infectious VV has also 
been recovered from faeces of mice after 20 days’ incubation at room 
temperature (Abrahao et al. 2009).
2.1.2 INFECTIONS IN HUMANS
Although vaccinia virus is not a naturally occurring virus, zoonotic vaccinia 
virus outbreaks have been reported in Brazil since 1999 (Kroon et al. 2011). In 
Brazil, the disease is called bovine vaccinia and it induces pox-like 
exhantematic lesions in the teats of dairy cows. Dairy workers get the infection 
from direct contact with infectious lesions. In addition to cattle and humans, 
VV has been detected in rodents, monkeys and horses, however, clinical signs 
may not always be seen (Kroon et al. 2011). 
Healthy people usually do not become infected with vaccinia virus, but 
serious complications may occur in an immunocompromised person (Kroon 
et al. 2011). The incubation period in humans is estimated to be 3-5 days. The 
first clinical signs include itchy, nodular lesions commonly seen on the hands. 
Nodules become papules surrounded by oedema and inflammation, and then 
usually 12 days after the appearance of signs, they form necrotic painful ulcers. 
Finally, the ulcer is covered by a scab, which sloughs off within 4 weeks of the 
beginning of the disease.
Strong inflammation reaction may result in lymphangitis and 
lymphadenopathy and systemic influenza-like symptoms, including fever, 
headache and myalgia (Kroon et al. 2011). Systemic signs usually last 2-5 days,
occurring 3-20 days after onset of skin lesions.
VV transmission is not well characterized, but it has been suggested that 
mice and rats are reservoirs in nature (Kroon et al. 2011). They ingest or 
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aspirate infectious scabs, milk, secretions or contaminated fomites, and 
transfer the virus to humans, cattle and wild animals via excrement, direct 
contact or predation.  VV is very stable in the environment and does not 
require direct contact for transmission. Instead, because of its stability, it is 
likely that VV spreads through fomites.
2.1.3 TREATMENT OF VACCINIA VIRUS INFECTIONS
The same drugs are effective for all OPV infections and are listed in Table 2
(Kroon et al. 2011). Cidofovir (Vistiside®) slows down replication of several 
DNA viruses by inhibiting viral DNA polymerase, and it is the only drug 
licensed against OPV infections. Vaccinia immunoglobulin (VIG) is the 
treatment of choice for severe VV infection (Cono et al. 2003), but its 
availability may be restricted.
ST-246 (tecovirimat) prevents formation of extracellular virus particles of 
OPV and was effective in relieving smallpox symptoms in non-human 
primates infected with variola virus (Mucker et al. 2013). In addition, it has 
proved safe in healthy human volunteers (Chinsangaram et al. 2012), and was 
used experimentally in one patient with progressive vaccinia infection in 
combination with VIG (Lederman et al. 2012). In Finland, ST-246 was 
successfully used to treat cowpox in one patient (personal communication,
Paula Kinnunen, The Finnish Defence Forces 2012). Pharmacokinetics of ST-
246 has also been evaluated in dogs (Amantana et al. 2013), so it could be used 
in pet dogs if necessary.
2.1.4 SMALLPOX VACCINATION
Wild-type VV has been given to hundreds of millions of people for active 
immunization against smallpox. The vaccine is given percutaneously with a
bifurcated needle. A papule forms at the inoculation site 2-5 days after 
vaccination. It first forms a vesicle and then a pustule, which dries out and 
forms a scab. Healing takes 14-21 days, and a pitted scar is left behind (Cono 
et al. 2003). 
The most common adverse event is flu-like symptoms. Serious adverse 
events comprise myocarditis, pericarditis, cardiomyopathy, generalized 
vaccinia, eczema vaccinatum, progressing vaccinia and post-vaccinial 
encephalitis (Cono et al. 2003). Serious but not life-threatening adverse events 
occur in 48–935 cases, life-threatening adverse events in 14–52 cases and 
lethal adverse events in 1.1–1.5 cases per million vaccines (Cono et al. 2003). 
Adverse events are more likely in persons who have cardiac disease, eye 
disease treated with corticosteroids, congenital or acquired immune deficiency 
disorders and history or presence of eczema or other skin conditions. In 
addition, infants aged < 12 months and pregnant women are predisposed to 
adverse events. Thus, smallpox vaccination is not recommended for these
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Table 2 Compounds with antiviral activity against vaccinia virus infection. Reprinted 
from Antiviral Research, Vol. 92, EG Kroon, BEF Moyta, JS Abrahao, FG daFoseca and S 
Trindade, Zoonotic Brazilian Vaccinia virus: From field to therapy, pp. 150-163. Copyright 2011,
with permission from Elsevier.
Therapeutic agent Mode of action Clinical trial Adverse event
Cell-penetrating 
peptides (CPP)
Inhibitor of viral 
entry
No Not tested in vivo
Cidofovir Nucleotide
analogues / DNA 
replication inhibition
Yes. Currently licensed 
for the treatment of 
cytomegalovirus
retinitis (Vistidine™). 
CMX001 is regulated 
for smallpox under the 
“Animal Rule” efficacy
Resistant strains 
may emerge; 
Nephrotoxicity (can 
be alleviate with the 
use of probenecid). 
CMX001 is not toxic 
and is orally 
available
STI-571
(Gleevec™)
Inhibitors of virus 
release and spread
Not for poxvirus 
treatment. Licensed for 
the treatment of certain 
types of cancer
Inhibition of the 
physiological 
functions by 
epidermal growth 
factor receptor and
Abl family kinases in 
non-infected cells
Gefitinib 
(Iressa™)
Inhibitors of virus 
release and spread
Not for poxvirus 
treatment. Licensed in 
US and Europe for the 
treatment of patients 
with non-small cell lung 
cancer (NSCLC)
Inhibition of the 
physiological 
functions  by 
epidermal growth 
factor receptor and
Abl family kinases in 
non-infected cells
ST-246
Inhibitors of virus 
release and spread 
(acts on F13L ORF 
of VACV)
FDA phase II clinical 
trials against smallpox 
virus
Resistant strains 
may emerge
RNA interference 
(RNAi)
Inhibition of protein 
expression
No Not described
Imiquimod Immune Response Modifiers (IRMs)
Licensed for the 
treatment of genital 
warts caused by 
human papillomavirus. 
A few studies 
conducted for the 
treatment of poxvirus 
infections
Moderate/severe 
local inflammatory 
response
Ethnopharmacological 
compounds Unknown No Not tested in vivo
individuals. VV can potentially induce an infection in a healthy person (Kotwal 
& Abrahams 2004).
Smallpox vaccination was discontinued in Finland in 198o (Finnish 
National Institute for Health and Welfare), and is not recommended in Europe 
since the risk of getting VV infection is minimal when correct laboratory 
working instructions are followed and the risk of adverse events from the 
vaccine outweighs the benefits (Kotwal & Abrahams 2004). However, in USA
vaccination is recommended for people working with VV or in the military. 
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The vaccine should be re-administered every 3-10 years to maintain antibodies
(Center for Disease Control and Prevention), implying that most Finns and 
other Europeans are not protected.
Wild-type VV usually spreads through direct contact with skin lesions and 
eyes, but does not pass through healthy skin (Kotwal & Abrahams 2004). 
Aerosol infections are unlikely (Cono et al. 2003). People in the smallpox 
vaccine risk group should not work with VV, although not all VV specialists 
think that pregnancy or mild skin disease prevents working with VV if safety
directions are followed (Kotwal & Abrahams 2004).
2.1.5 VACCINIA-RABIES RECOMBINANT VACCINE
Thymidine kinase (TK) -deleted Copenhagen strain VV expressing rabies virus 
glycoprotein has been used in a vaccinia-rabies recombinant vaccine for oral 
immunization of wild foxes and raccoons in Europe and North-America
(Brochier et al. 1996, Roess et al. 2012). Multiple studies have showed that the 
vaccine is safe in the target species and also in non-human primates (Brochier 
et al. 1996). The risk of spreading the virus into the environment is also 
minimal since the virus is not capable of horizontal transmission to other 
animals (Brochier et al. 1996). The potential risk would be recombination of 
the recombinant virus with a wild OPV if they infect and replicate in the same 
cell of the same host animal (Brochier et al. 1996).
More than 200 million oral rabies vaccine baits have been distributed into 
wildlife (Roess et al. 2012). To evaluate the risks of bait vaccines for humans 
and pets, a national surveillance was carried out in USA in 2001-2009 during 
which more than 80 million bait vaccines were distributed in 18 states (Roess 
et al. 2012). Six persons reported mild dermal symptoms, such as rash, itching, 
redness and swelling, after handling the rabies baits, and two individuals had 
more severe vaccinia infection (Rupprecht et al. 2001, Centers for Disease 
Control and Prevention (CDC) 2009). The first patient was on 
immunosuppressive medications for inflammatory bowel disease and she had 
fresh abrasions in her right arm and wrist that got contaminated with the 
liquid from the ruptured rabies bait vaccine (Centers for Disease Control and 
Prevention (CDC) 2009). Four days later, she developed poxlesion, erythema 
and oedema in the right hand. Due to underlying immunosuppressive disease 
and progression of the vaccinia infection, she received two doses of VIG and 
an investigational antiviral agent, ST-246. Four weeks after the incidence, her 
skin lesions had cleared and her inflammatory bowel disease was under 
control.
The second patient was a pregnant woman with epidermolytic 
hyperkeratosis (Rupprecht et al. 2001). Her dog bit her when she was 
removing a ruptured bait vaccine from the dog’s mouth. Three days after the 
incident, she noticed two blisters on her arm, which progressed to painful, 
erythematous, oedematous cellulitis and necrosis of the pustules. Necrotic 
areas were surgically removed, but she then developed generalized exfoliation 
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on her face and neck. One month after the dog bite, her lesions had healed and 
her pregnancy continued normally. Notably, the risk of getting VV infection 
from the rabies vaccines is very low since >200 million vaccinia baits have 
been distributed into nature (Roess et al. 2012). Adverse events reported in 
dogs eating vaccinia baits are mild and include lethargy, vomiting and 
diarrhoea (Roess et al. 2012).
The VV used in rabies vaccines is the Copenhagen strain and it has only a
TK-deletion, compared with our virus, which has both TK- and VGF-deletions,
making it more cancer-specific.
2.1.6 POXVIRUS INFECTIONS IN CATS
Poxvirus infections are not very common in cats, and only some 400 cases of 
Cowpox virus (CPXV) infections have been described in this species (Sandvik 
et al. 1998). The infection may actually be more common but may go 
unrecognized by veterinarians and owners. The symptoms consist of multiple 
skin lesions primarily seen on the head, oral cavity, neck, forelimb or paws, 
conjunctivitis and purulent ocular discharge. Rare systemic infections can be 
fatal in an immune-deficient cat or if co-infections occur or internal organs are 
infected. Infection is usually transmitted via hunting by infected rodents,
which serve as a reservoir for CPXV (Pfeffer et al. 2002). At least one case 
report exists in which CPXV was transmitted from a cat to a human (Hawranek 
et al. 2003). Cat-to-cat transmission is probably rare (Bennett et al. 1989). In 
contrast to CPXV, Lister strain VV showed low infectivity in cats and VV
infection seems to be self-limiting (Bennett et al. 1989).
2.1.7 VACCINIA VIRUS VECTORS IN CANCER THERAPY
VV has oncolytic properties, and thus, use of VV in cancer therapy is discussed 
in Section 2.3 Oncolytic viruses. 
Local immunotherapy with genetically attenuated VV vector NYVAC or 
canarypox virus expressing human or feline IL2 was used in cats with 
fibrosarcoma to prevent tumour recurrence after surgery and iridium-based 
radiotherapy (Jourdier et al. 2003). The tumour recurrence during a one-year 
follow-up was 39% in cats receiving NYVAC expressing human IL2 and 28% 
in cats receiving canarypox virus expressing feline IL-2 immunotherapy in 
addition to conventional therapy, compared with 61% in cats without 
immunotherapy. In fact, canarypoxvirus expressing feline IL-2 is currently 
commercially available in Europe for the treatment of feline fibrosarcomas.
2.2 SEMLIKI FOREST VIRUS
Semliki Forest virus (SFV) is an enveloped, positive strand RNA virus 
belonging to Alphavirus genus and Togaviridae family. SFV was first isolated 
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from mosquitoes in the Semliki Forest of Western Uganda in 1942. Since then,
multiple laboratory strains have been developed, the most common of which 
are presented in Table 3 (Griffin 2007). 
SFV, like other alphaviruses, are transmitted by mosquitos and can infect 
many vertebrate hosts. SFV is mainly found in Africa in mosquitos, including 
Aedes africanus and aegypti, but is also present in parts of Asia and possibly 
Central and Southern Europe (Lundström 1999). As a neurotropic and 
neuroinvasive virus, SVF-induced encephalitis has been reported in humans, 
horses and monkeys, and experimentally, mice, rats, guinea pigs, rabbits and 
hamsters have been infected (Griffin 2007).
Table 3 Most common Semliki Forest virus laboratory strains.
Strain Background Characteristics
A7 Mozambique Avirulent for an adult mouse, lethal encephalitis in 
suckling mice, resulting in death in 3-5 days
A7(74) Mozambique The least virulent strain derived from A7. Passaged 
through neonatal mouse brain. Lethal in mice 
??????????????ays
V12 Uganda, passed in mice in Bethesda
V13 Uganda, passed in mice in Bethesda Lethal encephalitis in mice, but young guinea pigs 
and rabbits survive with or without clinical signs
L10 Uganda, passed in mice in London Most virulent strain: lethal in mice in 4 days, and 
young guinea pigs and rabbits may get clinical 
symptoms, while adults will not
m9 Uganda, passed in mice in London Avirulent, derived from L10 by chemical 
mutagenesis
2.2.1 BIOLOGY OF SEMLIKI FOREST VIRUS
SFV virions are icosahedral and the diameter is 60-70 nm. The genome is 11-
12 kb in size and two-thirds of it codes for non-structural proteins at the 3’-
end and one-third for non-structural proteins at the 5’-end (Quetglas et al. 
2010).
Alphaviruses attach to cells via their E2 glycoprotein (Griffin 2007). There 
are probably multiple receptors that SFV uses, but the first one identified was 
the MHC class I molecule (Griffin 2007). However, SFV infection can occur 
without it. Virus enters the cell through endocytosis, and viral envelopes fuses 
with the endosome, which is induced by E1 glycoprotein and requires low pH
(Quetglas et al. 2010). The nucleocapsid is broken and the viral RNA is 
released into the cytoplasm, where RNA replication takes place (Quetglas et 
al. 2010). 
First, complementary minus-sense genomic RNA is produced in the first 3-
4 hours after infection, leading to amplification of viral genome and capsid 
protein formation. Synthesis and glycosylation of envelope proteins take place 
in the endoplastic reticulum, and glycosylation is completed in the Golgi 
complex. Viral DNA is packed into the capsid, which buds out from the cell 
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Replication cycle of SFV. Modified from Quetglas et al. (2010).
plasma membrane with envelope proteins. Release of progeny virus typically 
occurs 4-6 hours after infection (Griffin 2007, Quetglas et al. 2010). The 
replication cycle of SFV is presented in Figure 2.
SFV infection induces both cellular and humoral immune response (Griffin 
2007). SFV is sensitive to type I interferons (IFNs), which are part of the innate 
immunity against viral infection (Fragkoudis et al. 2007). IFN limits virus 
replication before specific immune response and is induced by inhibiting 
mRNA translation and later replication steps. Antiviral antibodies are usually 
detected in experimentally infected adult mice within 3-4 days of virus 
inoculation (Fazakerley et al. 1993). Virus-reactive lymphocytes appear in 
lymph nodes and circulation, and mononuclear cells in the site of infected 
tissue during the same time period in alphavirus infections (Griffin 2007). 
SFV is not very stable and infectious titre decreased by half in 3 days at 
22°C in water suspension in the dark (Benbough 1969), and the virus is 
inactivated in pH below 6 (White et al. 1981).
2.2.2 PATHOGENESIS IN VERTEBRATES
Pathogenesis of alphavirus in vertebrates is presented in Figure 3. SFV is 
transmitted into the vertebrate host via the bite of an infected mosquito. Virus-
contaminated saliva is deposited extravascularly into the host. The virus titre
is highest immediately after the mosquito is infected, and declines within 1-2
weeks, but the mosquito stays infected for the rest of its life (Griffin 2007).
The virus spreads from the subcutis to muscle, where it replicates and then 
travels into the circulation, or alternatively, infects Langerhans cells in the skin
KA 2014 
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Pathogenesis of alphaviruses in a vertebrate host. Reprinted from 
Immunological Reviews, Vol. 225, KD Ryman and WB Klimstra, Host responses to alphavirus 
infection, pp. 27-45. Copyright 2008, with permission from John Wiley and Sons, Inc.
and then spreads to local lymph nodes and into the circulation (Griffin 2007, 
Ryman & Klimstra 2008). In mice, significant viraemia is detected 24 hours 
after intraperitoneal injection of SFV, but declines after 48 hours and 
disappears from the blood in 4 days (Fazakerley et al. 1993). SFV probably 
enters the central nervous system (CNS) across cerebrovascular endothelial 
cells, but may travel through the choroid plexus and olfactory nerves as well
(Fazakerley 2002). In the CNS, SFV infects mainly neurons and 
oligodendrocytes and incidentally meningeal, edendymal or choroid plexus 
cells (Fazakerley 2002). It spreads in the CNS from one cell to another and 
through the cerebrospinal fluid. 
In brains, virulent SFV strains, such as L10, induce panencephalitis,
leading to death before the host immune system has time to stop the infection
(Fazakerley et al. 1993). Lethality of avirulent strains A7 and A7(74) depends 
on the age of the mouse (Bradish et al. 1971, Fazakerley et al. 1993). In neonatal 
mice, infection is lethal, but if infection occurs when mice are 14 days or older, 
they will survive and infection will remain local in the perivascular areas. Since 
the CNS is still maturing in neonatal mice, the neurons undergoing axogenesis 
and synaptogenesis are still sensitive to avirulent SFV infection (Fazakerley 
2002).
Neuronal death occurs in neonatal mice probably by apoptosis, whereas in 
older mice mature neurons are more resistant to infection (Fazakerley 2002). 
For example, A7(74) can replicate in mature neurons, but new virions cannot 
bud out from the cell (Fazakerley 2002). In an immunodeficient mouse, this 
can lead to persistent infection, but in an immunocompetent animal the host 
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immune system will clear out the virus. Infection of oligodendrocytes may 
result in demyelination (Griffin 2007).
Little is known about alphavirus infections in dogs. In an early study, SFV 
was given to 5- to 6-week-old healthy mongrel puppies via various routes,
including intraperitoneal, intranasal, intradermal, intracardial and 
intracerebral (Reagan et al. 1953). Each group had two puppies, except for the 
intraperitoneal group, which had only one puppy. Intraperitoneal and 
intracranial infection resulted in neurological signs in the puppies 7-10 days 
after virus administration, after which the dogs were sacrificed. The brains 
were collected and suspended, and the suspension was given intracranially to 
mice, which showed neurological signs 3-4 days after infection.
2.2.3 INFECTIONS IN HUMANS
SFV infections are quite common in humans in Africa based on serological 
surveys, which suggest that approximately 50% of the African population have
neutralizing antibodies (NAbs) against SFV (Mathiot et al. 1990). Most of the 
infections are symptomatic or mild and may be mixed with malaria or 
influenza (Mathiot et al. 1990).
One publication describes an outbreak of SFV infection in the Central 
African Republic in 1987 in which SFV induced a febrile illness especially in 
European soldiers recently arrived from France (Mathiot et al. 1990). Clinical 
signs included fever, headache, myalgia and arthralgia. SFV was isolated in the 
sera of 22 patients. During the same time period SFV was isolated from 
mosquitoes. Aedes africanus was the most common mosquito species affected 
in the area, but several others were infected as well, including Aedes, 
Anopheles, Conquilletidia, Culex, Eretmapodities and Manosonia species. In 
addition, four patients were evaluated for SFV antibodies 6-7 months after the 
disease; two had titres of 128, and the other two 32 and 64.
Apart from this outbreak, only one publication of human illness was located
in the literature. The publication describes a patient working in the laboratory 
with Osterrieth strain SVF (Willems et al. 1979). She had a one-year history of 
chronic purulent bronchitis, after which she developed severe headache and 
fever progressing to neurological signs, generalized seizure, coma and death. 
SFV-induced encephalitis was confirmed in autopsy.
Treatment of SFV infections consists of supportive therapy if the patient 
suffers from severe symptoms since no antiviral drugs against SFV exist 
(Krauss et al. 2003).
2.2.4 SEMLIKI FOREST VIRUS VECTORS IN CANCER THERAPY 
SFV, like other alphaviruses, is an attractive virus as a gene therapy vector in 
addition to oncolytic effects of the virus (Quetglas et al. 2010). Like VV, SFV 
has a broad tropism and can infect and replicate efficiently in multiple cell 
types from various host origins, including insects, avian and mammalian 
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species. Also like VV, SFV replicates fast and produces high levels of new 
virions. In contrast to VV, SFV has relatively small RNA, but it can be relatively 
easily manipulated, and viral RNA is infectious (Quetglas et al. 2010). Cancer 
vaccines expressing tumour-associated antigens and genes inducing 
apoptosis, or immunotherapy with vectors expressing cytokines or inhibiting 
angiogenesis are under investigation. The downside of alphavirus vectors is 
that the gene expression is transient. In cancer therapy, however, this may not 
be a problem, as the aim is to destroy the tumour as quickly as possible
(Quetglas et al. 2010).
2.3 ONCOLYTIC VIRUSES
Oncolytic viruses are cancer-specific viruses that kill cancer cells usually via 
immunogenic apoptosis, necrosis/necroptosis, pyroptosis or autophagy,
where the cell is destroyed through the actions of lysosomes (Guo et al. 2014). 
In classic apoptosis, the cell membrane stays intact and antigens or danger 
signals are not released outside the cell, whereas in immunogenic apoptosis, 
necrosis and pyroptosis the cell membrane breaks down and cell content is
released outside (Guo et al. 2014). Oncolytic viruses may have natural tropism 
for cancer cells, but commonly they have been genetically modified so that 
infection and replication take place only in cancer cells. Efficacy of oncolytic 
viruses can be increased by adding immunostimulatory genes to the viral 
genome. However, the immunotherapeutic effect is not only caused by 
transgenes, but also by the host’s antitumour immune response elicited when 
tumour cells die and release danger signals and tumour-associated antigens to 
dendritic cells (DCs) (Guo et al. 2014). The principles of oncolytic virus 
infection are shown in Figure 4.
The first approved oncolytic virus was recombinant human adenovirus type 
5 (ONYX-015®) (Woller et al. 2014). It has been on the market in China since 
2006 for the treatment of head and neck cancer. Various other oncolytic 
viruses that have been or are being evaluated in clinical trials in humans 
include vaccinia virus, other adenoviruses, herpesvirus, reovirus and vesicular 
stomatitis virus (National Cancer Institute 2014).
T-Vec (previously known as OncoVEXGM-CSF) is an attenuated herpes 
simplex virus 1 that expresses GM-CSF (Woller et al. 2014). The phase III trial 
did not improve overall survival for patients with advanced, unresectable 
melanoma, but a durable response rate was seen in 16% of patients relative to 
2% of controls. Interestingly, 11% of the patients had a complete response. The 
most common adverse events included fatigue, chills and fever. 
Reolysin is a reovirus that has been evaluated in phase II trials in patients 
with head and neck cancer, ovarian cancer and pancreatic cancer (Guo et al. 
2014). Reolysin in combination with paclitaxel and carboplatin induced one 
complete and 6 partial responses in 17 patients with head and neck cancer, and
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Oncolytic virus replicates in tumour tissue (A) but not in normal tissue (B). 
DAMPs, damage-associated molecular pattern molecules; APCs, antigen-presenting cells.
thus, is currently being evaluated in a phase III trial (Guo et al. 2014).
In veterinary medicine, use of oncolytic adenovirus has been reported in 
tumour-bearing pet dogs (Laborda et al. 2014), and pet dogs with cancer are 
being recruited for a clinical trial with VV (Gentschev et al. 2013, Genelux Inc. 
2013).
2.3.1 CHARACTERISTICS OF VACCINIA VIRUS AS AN ONCOLYTIC 
AGENT
VV has many features of a successful oncolytic virus (McCart et al. 2001, Guo 
et al. 2005, Kim et al. 2006, Kirn & Thorne 2009). VV is highly immunogenic 
and produces a strong cytotoxic T cell and antibody response. It also quickly 
destroys infected cells; the first infectious viruses are produced in 8 hours and 
infected cells die in 48-72 hours. 
VV spreads efficiently through the blood to the body and has a broad host 
range, including humans and numerous mammals; however, Chinese hamster 
ovary cells are not affected (McFadden 2005). VV has natural tropism for 
cancer cells probably due to a leaky vasculature. In addition, vaccinia virus has 
KA 2014 
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a large genome, which can accommodate multiple foreign genes to make new 
recombinant viruses. 
Finally, vaccinia virus does not integrate DNA into the host chromosome,
and a variety of antiviral agents are available to treat the infection if necessary. 
Both of these features increase the safety of the virus. 
Serious side effects are rare, and extensive experience with using the wild-
type vaccinia virus as a live vaccine in the smallpox eradication programme for 
millions of patients has proven its safety in clinical settings (Kirn & Thorne 
2009). 
2.3.2 ONCOLYTIC DOUBLE-DELETED VACCINIA VIRUS (VVDD)
Oncolytic vaccinia virus can be genetically modified to improve tumour 
specificity (McCart et al. 2001). These manipulations have resulted in the 
development of a tumour-selective double-deleted vaccinia virus (vvdd),
which is even safer than the wild-type vaccinia virus (McCart et al. 2001).
TK deletion renders the virus specific for cells highly active in the epidermal 
growth factor pathway (EGRF) since thymide triphosphatase is not present in 
non-dividing cells (McCart et al. 2001). EGRF-ras is upregulated in many solid 
tumours, but not in hematopoietic cancers (Elsedawy & Russell 2013), and is 
also expressed in canine and feline tumours (Bergvist & Yool 2010). 
During vaccinia infection vaccinia growth factor (VGF) stimulates the cells 
around infected cells to divide, allowing nucleotides for virus synthesis. 
Deletion of VGF results in selective replication in actively dividing cancer cells 
with an excess of nucleotides (McCart et al. 2001). In mouse models, vvdd was 
shown to be significantly more attenuated than single gene deleted viruses 
(McCart et al. 2001). 
2.3.3 ONCOLYTIC VVDD EXPRESSING HUMAN CD40 LIGAND AND 
TDTOMATO (VVDD-HCD40L-TDTOMATO)
To further improve efficacy of vvdd, the virus has been armed with human 
CD40 ligand (hCD40L). Construction of vvdd-tdTomato and vvdd-hCD40L-
tdTomato is presented in Figure 5. CD40L is a member of the TNF family. It 
enhances the antigen-specific T cell response by activating antigen-presenting 
cells (Bereta et al. 2004). Anti-proliferative, and pro-apoptotic effects of 
CD40L have also been reported in human CD40+ bladder, cervical and 
ovarian carcinoma cell lines (Vardouli et al. 2009). Apoptosis could be either 
caspase-8- and/or caspase-9-dependent in CD40+ cells (Ullenhag & Loskog 
2012). Further, CD40L is an important danger signal in thrombocytes and is 
released when blood vessels are injured, resulting in release of inflammatory 
cytokines, which may allow local infiltration of immune cells into the tumour 
(Ullenhag & Loskog 2012, Westberg et al. 2013).
Intratumoural adenovirus gene therapy coding for hCD40L (AdCD40L) 
was recently used in the treatment of 19 dogs with malignant melanoma as an
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Schematic drawing of virus construct of vvdd-tdTomato and vvdd-hCD40L-
tdTomato (with permission of Parviainen et al. 2014). ITR, inverted terminal repeats; TK*, 
tymide kinase open reading frame.
intratumoural injection (Westberg et al. 2013). As a proof of concept, complete 
response was seen in 5 and partial response in 8 dogs, including response 
shown in non-injected metastatic lesions. Infiltration of T and B lymphocytes
was detected in the tumour tissues, confirming immune stimulation in 8 of 11 
dogs. 
AdCD40L was also used in the treatment of humans with bladder cancer,
and it induced significant local immune stimulation with increased numbers 
of T cells and reduced numbers of tumour cells (Malmström et al. 2010). In 
the same study, AdCD40L treatment was associated with a decreased number
of T regulatory cells (Tregs). An immunosuppressive environment is necessary 
for tumour immune evasion and key players include CD4+ Tregs and myeloid-
derived suppressor cells, which either directly inhibit other immune cells or 
secrete immunosuppressive substances that prevent effector cell function or 
DC maturation (Ullenhag & Loskog 2012). In addition to decreased Treg 
counts, gene therapy with CD40L has promoted a myeloid cell population shift 
towards anti-tumoural M1 macrophages and granulocytic cells instead of 
immunosuppressive myeloid cells, thus reducing immunosuppression 
associated with the tumour (Liljenfeldt et al. 2014). 
tdTomato is a red fluorescent protein used in imaging of gene expression, 
protein localization and protein-protein interactions in vivo (Singer et al. 
2010). Virus-expressing tdTomato can be detected in infected cells, which 
helps in monitoring virus distribution, thus increasing the sensitivity of 
biosafety evaluation of the treatment agent. tdTomato imaging can also be 
useful in understanding the magnitude and persistence of anti-tumour effects 
in live animals.
Parviainen et al. (2014) have previously evaluated Western Reserve vvdd
expressing tdTomato and human (vvdd-hCD40L-tdTomato) or murine (vvdd-
mDC40L-tdTomato) CD40 ligand in cell cultures and murine models 
(Parviainen et al. 2014). Functional CD40L was expressed both in vitro and in 
tumours treated with the CD40L-expressing virus, but was not detected in the 
serum of the treated mice. Anti-tumoural efficacy was increased in a CD40-
sensitive xenograft model and the presence of lymphocytes, B cells, DCs and 
macrophages suggests anti-tumoural immunity induced by CD40L.
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2.3.4 ONCOLYTIC VACCINIA VIRUSES IN HUMAN MEDICINE 
Three oncolytic vaccinia viruses are currently under investigation in clinical 
trials (National Cancer Institute 2014). JX-594 and GLONC-1 have TK
deletion and JX-929 also has VGF deletion.
2.3.4.1 JX-594
The best-known oncolytic vaccinia virus in humans is JX-594, a TK-deleted 
Wyeth strain vaccinia virus expressing human GM-CSF and LacZ genes. 
Arming the virus with GM-CSF improves the efficacy of the virus by not only 
increasing the amount of granulocytes and macrophages produced from 
hematopoietic tissue but also recruiting them to the site of production, 
activating them and inducing anti-tumoural activity (Mastrangelo et al. 1999). 
In addition, GM-CSF stimulates proliferation and maturation of dendritic 
cells.  LacZ ?????????? ?-galactosidase, which is a functionally inactive but 
immunologically active protein, thus making detection of the virus possible by 
immunohistochemistry (Mastrangelo et al. 1999). It has also been used to 
assess immune response to the gene product (Mastrangelo et al. 1999).
JX-594 has been evaluated in patients with cutaneous (Mastrangelo et al. 
1999) and metastatic melanoma (Hwang et al. 2011), refractory or metastatic 
liver cancer (Park et al. 2008, Heo et al. 2013) and metastatic solid tumours 
(Breitbach et al. 2011), and is currently being tested in other tumour types as 
well (National Cancer Institute 2014). 
In the first published study, JX-594 was administered intralesionally twice 
weekly for 6 weeks for patients with cutaneous melanoma with a dose of 104 -
2 x 107 pfu/ lesion, corresponding to 104 -8 x 107 pfu/ session (Mastrangelo et 
al. 1999). One patient with only cutaneous metastasis had a complete 
response, one patient had a partial response and three patients had mixed 
responses. Two of the patients failed to respond to treatment. Adverse events 
included mild flu-like symptoms resolving in 24 hours, and local inflammation 
with dermal pustule formation was also seen. Biopsies confirmed infiltration 
of CD4+ and CD8+ lymphocytes, histiocytes and eosinophils and all of the 
patients formed antibodies to vaccinia virus.
In a dose escalation study, JX-594 was given intratumourally at a dose of 
108-3 x 109 pfu to patients with refractory primary or metastatic liver cancer 
every 3 weeks (Park et al. 2008). Both patients receiving the highest dose had 
grade III hyperbilirubinaemia, and thus, the maximum tolerated dose (MTD) 
was 109 pfu per person. All patients experienced mild to moderate flu-like 
symptoms, and a transient decrease in lymphocytes, platelets and red blood 
cells was seen in the first 3 days (Park et al. 2008). Neutrophilia associated 
with GM-CSF expression was detected in four of six patients with MTD. 
Treatment resulted in partial response in three patients, whereas six patients 
had stable disease and one patient progressive disease. Treatment response 
was not evaluated in four patients. Jx-594 genomes were detected in the blood 
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immediately after virus injection in all patients and then again 3-22 days later 
in 12 of 14 patients, consistent with virus replication. Virus was also detected 
in the distant, non-injected tumour, suggesting viral spreading through the 
blood.
To evaluate the optimal effective dose of the virus, 30 liver cancer patients 
were randomized to two treatment groups receiving either low-dose (108 pfu) 
or high-dose (109 pfu) JX-594 intratumourally three times two weeks apart 
(Heo et al. 2013). Survival of the patients receiving the high dose was 
significantly better than in the low-dose group (11.1 vs. 6.7 months). Mild flu-
like adverse events were monitored in all patients, and one patient suffered 
from severe vomiting and nausea requiring extended hospitalization. In 
addition, one patient had multiple skin pustules first noticed 4 days after the 
treatment, but which had disappeared within 6 weeks. Lymphopenia was 
reported in 4 of 30 patients and decreased haemoglobin in 3 of 30 liver cancer 
patients treated with JX-594. In addition, 9 of 14 patients had neutrophilia. 
Genomes of JX-594 were again detected in the blood, and in three patients 
they remained for up to 15-36 days.
Hwang et al. (2011) further evaluated intralesional administration of low-
dose JX-594 given once weekly over 6 weeks to patients with metastatic 
melanoma, and demonstrated viral replication, tumour necrosis, perivascular 
lymphocyte infiltration and expression of both transgenes in tumour biopsies. 
In addition, Breitbach et al. (2011) showed that intravenous administration of 
JX-594 also resulted in cancer-specific infection and replication of the virus in 
the biopsies obtained 8-10 days after infusion of JX-594. The virus dose in that 
study was 105/kg up to 109 pfu per person. 
In the both studies, side-effects associated with virus administration were 
mild and consisted mainly of flu-like symptoms, including fever, chills, fatigue, 
headache, nausea, vomiting, anorexia and myalgia. However, three patients
receiving the virus intravenously or in the liver developed pustules (Breitbach 
et al. 2011, Heo et al. 2013). Infectious JX-594 was not detected in urine or 
throat swabs from 14 patients (Park et al. 2008), but throat swabs from some 
patients revealed virus (EudraCT number 2009-011121-13). 
Due to the promising results, multiple clinical trials have been started in 
colorectal cancer, paediatric solid tumours and liver cancer (National Cancer 
Institute 2014).
2.3.4.2 JX-929
JX-929 (vvdd-CDSR) is a modification of JX-594, but it is a more potent 
Western Reserve strain and has both TK and VGF deletions (Zeh et al. 2015). 
As a transgene, JX-929 has cytosine deaminase (CD) and somatostatin 
receptor (SR) genes. CD is an enzyme that activates non-toxic prodrug 5-
fluorocytosine to cytotoxic drug 5-fluorouracil in infected cancer cells, where 
replication of the virus takes place. SR is used to image the virus by octreotide 
scintigraphy. 
Review of the literature
39
In the phase I dose-escalating study, the virus was given intratumourally to 
patients with solid tumours (Zeh et al. 2015). The results showed that the virus 
infects and destroys cancer cells and triggers anti-tumour immunity. The 
maximum tolerated dose was not reached in 16 patients recruited to the trial,
and the maximum feasible dose was determined to 3 x 109 pfu. 
The most common adverse events included fever and/or chills within 24 
hours of virus injection. Fifteen of 17 patients had fever, malaise and/or pain
5-15 days after virus administration associated with an inflammatory reaction 
to the virus. One patient suffered grade 3 pain at the tumour site that was 
thought to be associated with virus-induced inflammation; it resolved in 2 
days with narcotic pain medications.
In laboratory tests, mild elevations in liver values were detected in addition 
to increases in lactate dehydrogenase, which may have indicated tumour 
necrosis. Haematology showed a relative lymphopenia compared with 
baseline values, but no other obvious changes.
All patients had a significant increase in VV neutralizing antibodies. Viral 
genomes were detected in the blood of nine patients, all of whom ????????? ??8
pfu. Viral genomes re-emerged into the circulation in only two patients at later 
time-points. Seven patients had their tumours biopsied 8 days after virus 
injection, and infectious virus was recovered in four patients. In addition, one 
VV genome was detected in one biopsy. In two patients, virus was also 
recovered from non-injected lesions, suggesting systemic spreading of the 
virus. Saliva and urine were collected to determine shedding of the virus, but 
none of the samples was positive for infectious virus or VV genomes.
2.3.4.3 GL-ONC1
A third oncolytic vaccinia virus in clinical trials is GL-ONC1, which is a TK-
attenuated Lister strain vaccinia virus expressing green fluorescent protein 
(GFP), beta-galactosidase (LacZ) and beta-glucuronidase (GusA) (Jaime et al. 
2012). 
In a phase 1 trial in which the virus was given intravenously to patients with 
solid tumours, nine patients had stable disease for 8-48 weeks, but no 
complete or partial responses were seen. Dose-limiting toxicity was grade 3 in 
aspartate transaminase in one of six patients receiving 109 pfu. Other adverse 
events in 27 patients were mild flu-like symptoms, as with JX-594 and JX-929,
including fever, fatigue, musculoskeletal pain, nausea and vomiting.  In 
addition, virus-associated skin rash was seen in two patients; GFP expression 
was detected in the skin and infectious virus was isolated from the lesions.  
Infectious virus was also measured from blood, urine, faeces and sputum,
and one patient had positive results for 11 days. Antibody titre increased in all 
except one patient. Researchers were also able to show virus in one tumour 
biopsy by immunohistochemistry, confirming that the virus was able to reach 
the tumour after intravenous infusion.
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Clinical trials are currently ongoing in head and neck cancer, pleural cavity 
cancers and peritoneal carcinomatosis (Genelux Inc. 2013, National Cancer 
Institute 2014).
2.3.5 ONCOLYTIC SEMLIKI FOREST VIRUS
Oncolytic SFV has only been evaluated in preclinical trials. Replication-
deficient SFV expressing LacZ was first reported to infect and kill seven human 
prostatic cancer cell lines and human prostatic tissue explants (Hardy et al. 
2000). The infected cells detached from the culture surfaces and the basement 
membrane, and approximately half of the cells died 24-72 hours after 
infection.
Replication-competent vector VA7-EGFP from an avirulent A7(74) strain 
expressing enhanced green fluorescent protein was shown to infect and kill 
multiple tumour cell lines, including rat gliosarcoma and mouse 
neuroblastoma (Vähä-Koskela et al. 2003) and human melanoma, lung 
carcinoma and colon adenocarcinoma in vitro (Vähä-Koskela et al. 2006). 
Oncolytic capacity was also detected in human melanoma xenografts in severe 
combined immunodeficiency (SCID) mice with a single virus injection of 106
pfu intraperitoneally, intratumourally and intravenously (Vähä-Koskela et al. 
2006). However, some cancer cells were resistant to the virus, and after an 
initial response new tumour nodules were formed.
Efficacy of A7(74) and VA7-EGFP was evaluated in a subcutaneous A549 
human lung adenocarcinoma model in immunodeficient nude mice, and a rat 
BT4C glioma model in immunocompetent BDIX rats (Määtta et al. 2007). 
Intratumoural injection of SFV induced very strong antitumoural response,
whereas efficacy decreased when virus was given intravenously. When viruses 
were given intraperitoneally, no response was seen. The authors concluded 
that the difference in antitumoural efficacy between different routes was at 
least partly due to a strong type I IFN response. In the rat glioma model, an 
initial antitumoural response was also seen after intratumoural virus injection, 
but the tumours then started to regrow. Loss of antitumoural efficacy may 
have been due to NAbs.
VA7-EGFP also induced oncolysis in several osteosarcoma cell lines, and a
survival benefit was seen in an orthotopic osteosarcoma nude mouse model 
after intratumoural virus administration (Ketola et al. 2008). However, none 
of the mice was cured, and the authors suggested arming the virus with 
transgenes to improve efficacy. In addition, VA7-EGFP was assessed in an 
orthotopic lung cancer tumour model in immunodeficient nude mice (Määttä
et al. 2008). A significant improvement was observed in survival time when 
the virus was delivered intratumourally, but this was not the case after 
systemic delivery. This raised speculation about whether innate immune 
defence limits infectious capacity of the virus.
Further, VA7 vectors proved effective in killing several human glioma cell 
lines and resulted in a good antitumoural response in both subcutaneous and 
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orthopaedic human glioma xenografts in nude mice after intravenous 
administration (Heikkila et al. 2010).  
Later, it was reported that oncolytic efficacy of VA7 is prevented by IFN-?
(Ruotsalainen et al. 2012). VA7 was able to infect and kill mouse glioma cells 
GL261 and CT-2A in vitro, but when confluent, GL261 was resistant to 
infection. If cells were treated with mouse IFN-????????? ????????????????????
the virus was unable to replicate in the cells. Neither of the SFV vectors was 
able to infect GL261 and CT-2A tumours in an orthotopic xenograft nude 
mouse model. Pre-treatment of the mice with immunosuppressive 
cyclophosphamide or rapamycin did not improve their survival, although 
serum-neutralizing antibodies were significantly decreased. Thus, tumours 
that have mutations preventing type I IFN production or response appear to 
be sensitive to SFV vectors, while cells maintaining type I IFN response are 
resistant.
2.3.6 ONCOLYTIC VIRUSES IN VETERINARY MEDICINE
Multiple oncolytic viruses, such as adenovirus (Hemminki et al. 2003, 
Ternovoi et al. 2005, Le et al. 2006, Alcayaga-Miranda et al. 2010, Laborda et 
al. 2014), VV (Gentschev et al. 2009, Gentschev et al. 2010, Gentschev et al. 
2012, Patil et al. 2012), myxoma virus (Urbasic et al. 2012), canine distemper
virus (Suter et al. 2005) and parvovirus (Nykky et al. 2010), have been studied 
in canine cell lines and tumour xenografts. In addition, some of them, e.g.
vesicular stomatitis virus (VSV) (LeBlanc et al. 2013) and VV (Gentschev et al. 
2013), have been or are currently being evaluated in clinical studies in dogs 
suffering from cancer. In cats, only two publications on oncolytic viruses are 
available (MacNeill et al. 2012, Adelfinger et al. 2014).
2.3.6.1 Oncolytic vaccinia virus in preclinical studies in dogs
An unarmed oncolytic vaccinia virus from a Lister strain containing 
inactivated TK, GLV-1h68, has presented oncolytic efficacy in canine 
mammary adenoma and carcinoma cell lines and xenografts in nude mice 
(Gentschev et al. 2009, Gentschev et al. 2010). GLV-1h109, a derivate of GLV-
1h68 armed with an anti-VEGF (vascular endothelial growth factor) single-
chain antibody, also showed oncolytic potency against canine soft tissue 
sarcoma and prostatic carcinoma in an in vivo model and induced intense 
intratumoural infiltration of host immune cells in tumour-bearing mice 
(Gentschev et al. 2012, Patil et al. 2012). However, an unarmed less virulent 
Lister strain virus, LIVP1.1.1, showed even better oncolytic efficacy against 
canine soft tissue sarcoma in preclinical studies (Gentschev et al. 2012), thus 
resulting in isolation of LIVP6.1.1 (Gentschev et al. 2013). 
LIVP6.1.1 is a wild-type Lister strain vaccinia virus with no genetic 
manipulations, but TK is naturally inactivated and the virus has different 
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mutations than GLV-1h68 (Gentschev et al. 2013). LIVP6.1.1 is able to kill 
canine soft tissue sarcoma, melanoma, osteosarcoma and prostatic sarcoma 
cell lines, and efficacy has been shown in soft tissue sarcoma and prostatic 
carcinoma xenografts as well (Gentschev et al. 2013). Due to promising results 
in preclinical trials, LIVP6.1.1, also called V-VET1, is currently being evaluated 
in clinical trials in pet dogs with naturally occurring cancer (Gentschev et al. 
2013, Genelux Inc. 2013).
2.3.6.2 Oncolytic adenovirus in dogs
Adenoviruses are the best-evaluated oncolytic viruses in dogs. A conditionally 
replicating canine adenovirus type 2, OC-CAVE1, was reported to infect, 
replicate in and kill canine cancer cells in osteosarcoma laboratory cell line and 
tumour biopsy obtained from a naturally occurring canine osteosarcoma 
(Hemminki et al. 2003). In addition, OC-CAVE1 had antitumoural efficacy 
against canine osteosarcoma xenograft in a nude mouse model. Also human 
adenovirus type 5 was able to infect and replicate in canine mesenchymal and 
epithelial cancer cell lines, including osteosarcoma, mammary carcinoma and 
melanoma cells (Ternovoi et al. 2005).  
Further, efficacy of canine adenovirus type 2- and 5-based oncolytic viruses 
was reported in canine osteosarcoma and melanoma in other preclinical 
studies (Le et al. 2006, Alcayaga-Miranda et al. 2010, Laborda et al. 2014). 
In order to test the viruses in pet dogs, initial toxicity of osteosarcoma-
targeted canine adenovirus (CAV)-2 was evaluated in six healthy laboratory 
dogs (Smith et al. 2006). Only mild adverse events, such as diarrhoea, were 
detected. In haematology, neutrophil count decreased in all dogs; 3 dogs had 
grade 1 and 1 dog grade 4 neutropenia. Lymphocytes increased in 5 of the 6
dogs, and in 3 dogs the values were above the reference range. The dogs were 
euthanized 4 days after the virus administration; three dogs already had 
increased serum NAbs. Viral genomes were found in the blood until 
euthanasia, and low numbers of genomes were detected in some faecal and 
urine samples. Liver and spleen had the highest viral copy numbers, but low 
numbers were also detected in lung, lymph node, bone marrow and muscle,
suggesting that the virus can spread effectively in the body and infect multiple 
tissues.
Recently, pRb-responsive, RGD-modified and hyaluronidase-armed 
canine oncolytic adenovirus was administered intratumourally to six pet dogs
(Laborda et al. 2014). Two dogs had appendicular osteosarcoma, and other 
tumours included sweat gland adenoma, mast cell tumour, fibrosarcoma and 
neuroendocrine hepatic carcinoma. Sweat gland adenoma and mast cell 
tumour showed partial response, but progressed again 11 months after virus 
treatment. Fibrosarcoma was surgically removed 15 days after virus treatment 
and the dog stayed tumour-free for at least 8 months. Although no evidence of 
virus-associated adverse events were seen, one dog died due to disseminated 
intravascular coagulation following tumour lysis and one dog had a self-
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inflicted wound that could have been related to tumour necrosis induced by 
the virus. All dogs, except one, had increased CAV-2 antibodies. The dog with 
the highest baseline CAV-2 titres had evidence of viral replication and necrosis 
in both inoculated and non-inoculated tumours, suggesting that high antibody 
titres may not prevent oncolytic potency of the virus. qPCR revealed 
adenovirus genomes in the blood soon after virus inoculation, but these 
decreased over time. The last positive sample was collected one week after 
virus treatment. 
2.3.6.3 Vesicular stomatitis virus in dogs
A genetically modified VSV expressing IFN-?? ???? ???-protein for nuclear 
imaging, VSV-????-NIS, was also evaluated in a dose escalation study in five
healthy Beagle dogs (LeBlanc et al. 2013). The highest dose induced severe 
liver toxicity and shock, leading to euthanasia of the dog. Other adverse events 
included fever, nausea, lymphopenia and oral lesions. Oncolytic VSV is 
currently undergoing a phase 1 trial in human liver cancer patients (National 
Cancer Institute 2014).
2.3.6.4 Other oncolytic viruses in dogs and cats
Other oncolytic viruses that have been studied in canine cancers include 
reovirus (Hwang et al. 2013, Hwang et al. 2014, Igase et al. 2015), myxoma 
virus (Urbasic et al. 2012), canine distemper (Suter et al. 2005) and parvovirus 
(Nykky et al. 2010).
Canine mast cell tumour cell lines were highly sensitive to reovirus-induced 
oncolysis (Hwang et al. 2013), but this was detected in only 4 of 10 canine 
lymphoma cell lines (Hwang et al. 2014). Tumour regression was shown both 
in the mast cell tumour and lymphoma xenograft mouse model and in primary 
canine mast cell tumour biopsies in vitro (Hwang et al. 2013, Hwang et al. 
2014). Recently, oncolytic potency of reovirus was also demonstrated in canine 
mammary gland tumor, osteosarcoma and malignant melanoma cell lines
(Igase et al. 2015).
Myxoma virus was able to kill multiple canine cancer cell lines grown from 
surgical biopsies (Urbasic et al. 2012), whereas distemper virus, evaluated in 
cervical tumour-derived cell lines and in T and B cell lymphoma biopsies, 
induced apoptosis (Suter et al. 2005). In addition, parvovirus was also able to 
induce apoptosis in canine fibroma cells (Nykky et al. 2010). 
One publication has reported the use of myxoma virus in two feline 
carcinoma cell lines (MacNeill et al. 2012). Myxoma virus is a rabbit-specific 
pathogen that is non-pathogenic in cats and other vertebrates (Bull & 
Dickinson 1937), and thus, is a potential candidate as an oncolytic agent in 
cats. The tested myxoma virus was able to transduce and induce apoptosis in 
feline squamous cell carcinoma SCCF1 cells and feline mammary carcinoma 
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STUDE cells 48 hours after infection (MacNeill et al. 2012). Although SCCF1 
was less sensitive for viral oncolysis than the other feline carcinoma cell line 
STUDE, isolated from mammary tumour, myxoma virus was able to enter and 
induce early protein expression in SCCF1 cells. It also induced a cytopathic 
effect (CPE) in SCCF1 cells, but CPE was not seen until 24 hours after infection 
compared with STUDE cells, where CPE was detected already 12 hours post-
infection (p.i.). The virus was able to produce infectious virions in both cell 
lines, although the amount of virions was less than with a fully-permissive cell 
line. 
Recently, a new recombinant oncolytic VV strain, GLV-5b451, was 
investigated in feline mammary carcinoma cell line DT09/06 isolated from a 
patient cat (Adelfinger et al. 2014). The virus was derived from LIVP 6.1.1 and 
expresses the anti-VEGF single-chain antibody GLAF-2 against feline 
mammary carcinoma. glaf-2 gene was inserted into the J2R thymidine kinase
coding locus, and it was under the control of the VV synthetic early-late  
promoter. The virus efficiently killed feline mammary carcinoma cells and 
significantly regressed tumour growth in a nude mouse xenograft model. The 
virus also induced VEGF-antibody synthesis, which caused a reduction of 
VEGF in the tumours and inhibited angiogenesis.
2.3.7 SAFETY OF USING ONCOLYTIC VACCINIA AND SEMLIKI 
FOREST VIRUS IN VETERINARY MEDICINE
Safety of humans is an important consideration when treating pets with 
potential human pathogens. Vvdd is cancer-specific so it should not replicate 
in normal tissues or cause disease in healthy individuals, but smallpox vaccine, 
which is not cancer-specific, can cause adverse events in immunosuppressed 
people including cancer patients. Oncolytic VV has only been evaluated in 
cancer patients, and thus, the possibility of adverse events, especially in other 
immunosuppressed individuals, should not be ignored. In addition, VV is very 
stable in organic material, unlike SFV.
SFV infection is usually mild in humans and transferred by mosquitoes 
living in tropical areas (Mathiot et al. 1990), so outside tropical regions SFV 
infection is not a concern, although aerosol infection is possible (Krauss et al. 
2003). In epidemic areas, a mosquito bite during viraemia could result in SFV 
transmission.
Saliva from VV-treated dogs may pose a risk via shedding and licking, 
especially for immunosuppressed individuals with skin lesions. The risk of 
complications should be low, as vvdd is much less pathogenic than the wild-
type VV used in smallpox vaccination. In addition, virus expressed tdTomato
and ?-galactosidase can be used for monitoring of excretions and possible pox
lesions.
Since pet dogs urinate and defecate outside and it is difficult to completely 
collect the urine, urine from virus-treated dogs may pose an environmental
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hazard. The risk is minimal for faeces, which can be easily collected and 
disposed after inactivation with disinfectants, heat or UV light.
In humans, infectious VV was detected in urine, faeces and sputum in one 
of 27 patients receiving oncolytic VV (Jaime et al. 2012), but was not detected 
in urine or throat swabs from 14 patients treated with other oncolytic VV (Park 
et al. 2008) or in urine or saliva of 16 patients receiving vvdd (Zeh et al. 2015). 
However, infectious oncolytic VV has been detected in throat swabs (EudraCt 
2011-000051-16), and thus, infectious VV could also be found in canine 
secretions and possible spreading of the virus via secretions should not be 
neglected.
In theory, recombination of the virus in the environment is possible if the 
cell is co-infected with vvdd and another orthopoxvirus at the same time, 
although double-strand DNA viruses are usually stable (Brochier et al. 1996). 
Since the vvdd-tdTomato-hCD40L virus does not contain any genes increasing 
pathogenicity and transgenes make it more immunogenic, the new virus would 
be less likely to induce infection than wild-type orthopoxviruses.
The biggest risk for VV spreading would be a superficial ulcerated tumour 
or a skin lesion since pox viruses usually spread with direct contact through 
skin lesions and eyes. VV does not pass healthy skin (Kotwal & Abrahams 
2004) and aerosol infection is unlikely (Cono et al. 2003). Pox-like skin lesions 
have been reported in a few human cancer patients receiving oncolytic VV 
(Breitbach et al. 2011, Heo et al. 2013), and classic vaccinia necrosum was 
reported in VV-injected skin lesions in cancer patients receiving vvdd (Zeh et 
al. 2015). Skin lesions were also reported in laboratory Beagles receiving an 
intradermal inoculation of TK-deleted VV (Appel & Paoletti 1988). The dogs 
were in close contact with dogs not receiving the virus, and none of the latter 
group had induction of antibodies or skin lesions, suggesting that the virus 
does not spread from inoculated dogs to non-inoculated dogs.
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3 AIMS OF THE STUDY
The primary goal of this study was to evaluate preclinically whether genetically 
modified double-deleted oncolytic vaccinia virus (vvdd) and Semliki Forest 
virus (SFV) could be used in the treatment of canine and feline cancers.
Specific aims of the study were as follows:
1. To test the effect of vvdd and vvdd-expressing human CD40 ligand on 
dog cancer cell lines and tumour tissues and to determine the efficacy 
of vvdd in nude mouse models with tumour xenografts (I).
2. To test the effect of vvdd and vvdd-expressing human CD40 ligand on 
feline squamous cell carcinoma (SCCF1) cell lines and to evaluate 
production of oncolytic vaccinia virus in them (II).
3. To determine the safety and biodistribution of vvdd-expressing 
human CD40 ligand in healthy dogs (III).
4. To test the effect of attenuated SFV on dog cancer cell lines and to
determine the safety and biodistribution of attenuated SFV in healthy 
dogs (IV).
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4 MATERIALS AND METHODS
4.1 CELL LINES
Two canine osteosarcoma cell lines (Abrams and D17), one prostatic 
carcinoma cell line (ACE-1) and one feline squamous cell carcinoma cell line 
(SCCF1) were used in the study. In addition to cancer cell lines, the Madin-
Darby canine kidney (MDCK) cell line served as a control for normal cells. 
Abrams was kindly provided by Dr. D. Vail (University of Wisconsin-
Madison, WI, USA), D17 by Dr. R. Alemany (Catalan Institute of Oncology, 
Barcelona, Spain), ACE-1 and SCCF1 by Dr. T. Rosol (Ohio State University, 
Columbus, OH, USA), and MDCK by Dr. H. Sariola (University of Helsinki, 
Finland). 
Other cell lines used included Vero cells originating from African green 
monkey kidney epithelium, U2OS originating from a human osteosarcoma
and BHK-21 originating from baby hamster kidney cell line, all received from 
the American Type Culture Collection (Manassas, VA, USA). In addition, A549 
cells originating from human lung adenocarcinoma epithelium were obtained
from the National Cancer Institute (Bethesda, MD, USA) and murine 
melanoma cell line B16-OVA was kindly donated by Dr. R. Vile (Mayo Clinic, 
Rochester, MN, USA).
All cells were cultured in 5% CO2 at 37°C in recommended growth media 
purchased from Lonza (Veviers, Belgium) (I-III) or Sigma Aldrich (St. Louis, 
MO, USA) (IV) and supplemented with 10% foetal calf serum (FCS), 1% L-
glutamine and 1% penicillin-streptomycin (P-S), unless otherwise specified.
Cells for SFV experiments had only 5% FCS and were complemented with 25 
mM HEPES. Cell lines are summarized in Table 4.
4.2 VIRUSES
The VVs used were all cancer-specific vvdd of the Western Reserve strain and 
have total deletion of the VGF gene and partial deletion of the TK gene. All 
viruses also had insertion of the LacZ gene in the VGF site coding the inactive 
but immunogenic beta-galactosidase enzyme. Furthermore, vvdd-luc had
insertion of luciferase, vvdd-tdTomato tdTomato and vvdd-CD40L-tdTomato 
human CD40L and tdTomato genes. The viruses were engineered as 
previously described (Guse et al. 2010, Parviainen et al. 2014).
Vvdd-luc was grown on Vero cells, and vvdd-tdTomato and vvdd-hCD40L-
tdTomato on A549 cells. Viruses were purified using sucrose gradient 
centrifugation, and plaque assay was used to measure virus titres (Earl et al. 
1998). Titring of vvdd-luc was performed on Vero cells, and titring of vvdd-
tdTomato and vvdd-CD40L-tdTomato on A549 cells.
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Table 4 Cell lines used in Studies I-IV.
Cell line Origin Growth media Study
Abrams Canine osteosarcoma DMEM I, IV
ACE-1 Canine prostatic carcinoma F12-K I
D17 Canine osteosarcoma DMEM I, IV
MDCK Madin-Darby canine kidney cell line EMEM I
SCCF1 Feline squamous cell carcinoma DMEM with 4.5 g/l glucose II
A549 Human lung carcinoma DMEM I, II, III, IV
U2OS Human osteosarcoma DMEM I, II, III, 
Vero African green monkey kidney 
epithelium
DMEM with 4.5 g/l glucose 
DMEM with 1 g/l glucose
I, II, III, IV
B16-
OVA
Murine melanoma cell line 
expressing ovalbumin
DMEM II
BHK-21 Baby hamster kidney cells DMEM IV
DMEM, Dulbecco's Modified Eagle Medium growth media
EMEM, Eagle's minimal essential medium
F-12K, Kaighn's Modification of Ham's F-12 Medium
Table 5 Table of viruses used in Studies I-IV.
Virus name Virus Transgene Study Reference
Vvdd-luc TK- and VGF-deleted 
Western Reserve vaccinia 
virus 
Luciferase I Guse et al. 
2010
Vvdd-tdTomato TK- and VGF-deleted 
Western Reserve vaccinia 
virus 
tdTomato I, II, III Parviainen et 
al. 2014
Vvdd-hCD40L-
tdTomato
TK- and VGF-deleted 
Western Reserve vaccinia 
virus 
human CD40L, 
tdTomato
I, II, III Parviainen et 
al. 2014
Ad5/3-hTERT-
CD40L
Serotype 5 adenovirus with 
knob replacement from 
serotype 3 adenovirus
Human 
telomerase 
reverse 
transcriptase
and CD40L
II Diaconu et 
al. 2012
Ad5/3-hTERT Serotype 5 adenovirus with 
knob replacement from 
serotype 3 adenovirus
Human 
telomerase 
reverse 
transcriptase
II Diaconu et 
al. 2012
A7(74) Attenuated Semliki Forest 
virus
IV Bradish et al. 
1971
VA7-EGFP Attenuated Semliki Forest 
virus
Enhanced green 
fluorescent
protein
IV Vähä-
Koskela et al. 
2003
Ad5/3-hTERT-CD40L and Ad5/3-hTERT were engineered and produced
according to a previous description (Diaconu et al. 2012). The VV for the dog 
study was produced in GMP-quality A549 cells, and infectious titre was 
measured by median tissue culture infective dose (TCID50) in A549 cells 
(Hemminki et al. 2011).
Materials and methods
49
The replication-competent, attenuated A7(74) strain of SFV was kindly 
provided by Dr. R. E. Shope (Yale Arbovirus Research Unit, Yale School of 
Medicine, New Haven, CT, USA) and generated as described elsewhere
(Bradish et al. 1971). The replication-competent, attenuated VA7-EGFP 
expressing enhanced green fluorescent protein used in in vitro studies has also 
been described previously, as has generation of the infectious cDNA clone and 
expression vector (Vähä-Koskela et al. 2003). Viruses were amplified in baby 
hamster kidney BHK-21 cells, and infectious titre was measured by plaque 
titration (Ruotsalainen et al. 2014). A list of the viruses used in Studies I-IV is 
presented in Table 5.
Inactivation of vvdd-luc was performed with ultraviolet light following a
previously described protocol (II) (Tsung et al. 1996). The virus was first 
incubated at room temperature for 10 min in 10 μg/ml psoralen in Hanks 
balanced solution with 0.1% FCS and then irradiated for 3 min in a CL-100 UV 
cross-linker (UVP, Cambridge, UK) with 365 nm ultraviolet A light.
4.3 IN VITRO EXPERIMENTS
4.3.1 TRANSDUCTION ANALYSIS (I, II)
Transduction of vvdd-luc was performed by plating 100 000 cells per well in a 
24-well plate in growth medium (GM) with 5% FCS. After a 48-h incubation, 
the cells were washed once with 2% FCS GM and infected in triplicate with 
different concentrations of virus in 2% FCS GM for 30 min. Infected cells were 
then washed once with 10% FCS GM and incubated for 4 h. Finally, cells were 
lysed and luciferase activity was measured according to the manufacturer’s 
instructions (Luciferase Assay System, Promega, Madison, WI, USA). 
Transduction of viruses expressing tdTomato was performed similarly, except 
that cells were incubated for 24 h and fluorescence of tdTomato was monitored 
by fluorescence microscope (Olympus 1X71 inverted microscope, Olympus, 
Tokyo, Japan) at 8, 12 and 24 h p.i.
4.3.2 CYTOTOXICITY ASSAYS (I, II, IV)
Cell viability after vvdd-tdTomato and vvdd-hCD40L-tdTomato viral infection 
was measured using a colorimetric cell lysis test (MTS). Ten thousand cells per 
well were plated on 96-well plates in 5% FCS GM and incubated for 48 h, after 
which wells were infected in triplicate with different concentrations of virus 
for one hour in 2% FCS GM. After that, 5% FCS GM was added to the wells,
and cells were incubated until cell viability was measured by MTS according 
to the manufacturer’s instructions (Cell Titer 96 AQueous One Solution 
Proliferation Assay, Promega). Inactivated vaccinia virus was used as a non-
replicating control. Inactivation of the virus was performed as described 
elsewhere (Guse et al. 2010).
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For infection with SFV (IV), twenty-five thousand cells per well were plated 
on 48–well plates. The next day, the cells were infected in triplicate with VA7-
EGFP at 1, 0.1 and 0.01 multiplicity of infection (MOI). Virus infection was 
followed by fluorescence of EGFP, and cytopathic effect was monitored by 
using a phase contrast microscope (Zeiss Axio Observer Z1, Zeiss, Oberkochen, 
Germany) at 24 and 48 h after infection. Immediately after that, crystal violet 
staining was performed to confirm cytopathicity, and the plates were imaged 
with a digital camera. Then, crystal violet was dissolved in room temperature 
in 250 μl of 10% acetic acid for 20 min in a shaker to quantify cell viability. 
Absorbance of the dissolved dye from the samples transferred to a 96-well 
plate was measured at a wavelength of 595 nm with a plate reader (VICTOR2, 
PerkinElmer, Waltham, MA, USA). Growth media served as a negative control.
4.3.3 VIRAL REPLICATION KINETICS ANALYSIS (I, II)
Two hundred thousand cells were plated on 24-well plates in 5% FCS GM and 
infected the next day with vvdd-tdTomato and vvdd-hCD40L-tdTomato in 
triplicate at 0.01 pfu per cell for one hour in 2% FCS GM. Then, 5% FCS GM 
was added to the wells, and cells were detached by scraping them with the 
bigger end of a pipet tip and collected with GM 24, 48 and 72 h after and frozen 
at -80°C. After three freezing-thawing cycles, supernatant was separated from 
cell pellet by centrifuging at 200 G for 5 min and collected, and a standard 
plaque forming assay (Earl et al. 1998) was performed in duplicate to 
determine the amount of infectious virus.
4.3.4 CLONAL ASSAY (I, II)
Clonal assay was performed for ACE-1 and SCCF1 cell lines. Ten thousand and 
50,000 cells grown on 6-well plates and infected after a 48-h incubation for 
one hour with 10 pfu per cell in 2% FCS GM. Cells were collected with 
supernatant at 24 and 72 h by scraping from the wells. One hundred thousand, 
1000, 100 and 10 cells were plated in triplicate on 6-well plates and standard 
plaque forming assay was performed after 6-7 days to count the plaques. 
4.3.5 QUANTIFICATION AND INFECTIVITY OF THE PRODUCED
VIRIONS IN IN VITRO SCCF1 CELLS (II)
VV was extracted and purified from infected A549 and SCCF1 cells to monitor
the amount of virus produced by the cells. To determine the production rate of 
secreted virions, the supernatant of the infected SCCF1 cells was also collected 
at different time-points for plaque assay. Collected supernatant was also used 
to infect either SCCF1 or A549 cells to observe the efficacy of secondary 
infection, and a transduction assay was performed as described above.
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4.3.6 NEUTRALIZATION ASSAY IN SCCF1 CELLS (II)
Supernatant collected from VV-infected SCCFI cells was incubated for one
hour at 37°C with or without NR-417 monoclonal anti-vaccinia antibody 
(BeiResources, Manassas, VA, USA), after which a standard plaque assay was 
performed to determine the amount of neutralized virus.
4.3.7 ELECTRON MICROSCOPY OF SCCF1 CELLS (II)
A negative staining of whole-mounted viral particles and a thin sectioning of 
resin-embedded cells with viruses were used in this study.
The negative staining method was used to investigate surface structures of 
purified, whole-mounted VV particles in the supernatant of infected SCCF1 
and A549 cells. The method detects viral particle as a whole in three
dimensions. 
First, the supernatant collected from infected cells was filtered through a
sucrose cushion to purify the virus particles as described elsewhere (Guse et 
al. 2010). Then, one droplet (10-20 μl) of virus suspension was applied on top 
of the formvar-carbon coated electron microscopy (EM) specimen supporting 
grids. After absorbing for one minute, the suspension was blotted away with
Whatman filter paper and one droplet (30-40 μl) of negative stain and 2% 
potassium phosphotungstate (KPT) at pH 7.2 was added on top of the grids for 
30 s to stain the virus. Finally, the stain was blotted away and the grids were 
air-dried for 2 min and loaded into EM for inspection. The virions are 
predominantly attached to the grid with the largest, flat surface and face up,
which is typical for asymmetrical particles.
Resin-embedded thin-section EM was used to study the internal structure 
of viral particles and infected host cells. Unlike the negative staining method, 
thin sections allow evaluation of VV structures in any orientation since the 
embedding and cutting direction are random relative to the particles. 
Initially, VV-infected SCCF1 and A549 cells were fixed immediately out of 
incubator with 2.5% glutaraldehyde in 0.1 M phosphate buffer at pH 7.4 for 30 
min 48 h p.i. on-site in the culture dish. The cells were then scraped off the 
dish, centrifuged and collected as a small pellet of 2-3 mm3. For further 
fixation, fresh glutaraldehyde fixative was added on top of the pellet for half 
an hour. After that, the pellets were post-fixed for one hour with 2% osmium 
tetroxide, dehydrated in series of ethanol and embedded in LX-112 resin. 
Ultra-thin sections were cut at a thickness of 60-80 nm, mounted on 200 mesh 
EM specimen supporting grids, stained with uranyl acetate and lead citrate in 
an automatic stainer (Leica EMstain, Leica microsystems, Austria) according 
to the manufacturer´s instructions and examined by EM. 
Examination of both negative stained specimen and thin section was 
performed by JEM 1400 transmission electron microscope (TEM) (JEOL, 
Tokyo, Japan) at 80 kV. Side-mounted Morada TEM digital camera (Olympus 
Soft Imaging Solution GMBH, Munster Germany) was used to take digital 
electron micrographs. Brightness and contrast of the images were adjusted by 
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iTem software from the camera manufacturer, and Adobe Photoshop software 
was used for analysis.
4.3.8 CELL DEATH TYPE ASSESSMENT (I)
For the assessment of the type and degree of cell death in association with viral 
infection, D17 osteosarcoma monolayers were infected with vvdd-luc at 0.1 pfu 
per cell. The cells were collected at 24 and 48 h after infection with trypsin 
digestion and centrifuged at 61 g for 10 min. The supernatant was replaced by 
phosphate-buffered saline (PBS). After this procedure had been repeated 
twice, the resulting cell pellet was fixed for 24 h in 4% paraformaldehyde in 
PBS pH 7.4 and then paraffin wax-embedded, or fixed with 2.5% 
glutaraldehyde in 0.1 M sodium cacodylate buffer for TEM. Uninfected cells 
served as the control.
The paraffin-embedded cell pellet was sectioned in slices of 3-5 μm and 
stained with haematoxylin and eosin (HE). To recognize cleaved caspase-3-
positive apoptotic cells, immunohistological stain was performed with rabbit 
anti-cleaved caspase-3 antibody (Cell Signaling Technology, Inc., Danvers, 
MA, USA) (see Section 4.4.3. Post-mortem examination, histology and 
immunohistology).
Cell pellets were washed for 90 min in 0.1 M sodium cacodylate buffer, 
post-fixed in 1% osmium tetroxide(aq) and routinely resin-embedded for 
TEM. Semi-????????????????????????? ??? stained with toluidine blue and used 
to recognize areas of interest to prepare 80-nm ultrathin sections. Philips 
208S Transmission Electron Microscope (Koninklijke Philips Electronics 
N.V., Eindhoven, the Netherlands) was used to examine the samples at 80 kV.
4.4 IN VIVO EXPERIMENTS
4.4.1 ETHICAL CONSIDERATIONS
The in vivo mice studies were approved by the National Animal Experiment 
Board of the Regional State Administrative Agency of Southern Finland (no. 
ESLH-2009-06696/Ym-23). The VV dog experiment and the SFV experiment 
were approved by the same agency (nos. ESAVI/4953/04.10.03/2011 and
ESAVI/3231/04.10.07/2013, respectively).
All animals were purpose-bred and the dogs were retired breeding dogs 
slated for euthanasia. The dogs had been vaccinated regularly against canine 
distemper, hepatitis, parvovirus, parainfluenza, leptospirosis and rabies and 
had been dewormed regularly.
All animals were housed in isolation wards under standard condition and 
they had free access to water at all times. Mice were fed ad libidum, whereas 
the dogs were fed twice daily with commercial laboratory animal food. The 
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dogs in both studies were housed together in the same kennel (area ca. 12 m2)
to increase their welfare, but were separated for 24 h after VV infusion to allow 
video camera monitoring. The dogs had smaller cages in their kennels where 
they were able to hide and sleep. They were also able to access the roof of the 
cages. The dogs had blankets, toys and bones available, and twice daily the 
personnel spent some time playing with the dogs.
4.4.2 NUDE MOUSE XENOGRAFT MODEL (I)
Six 4-week-old nude HsdCpb: NMRI – Fox1 Nu/Nu female mice purchased 
from Harlan Laboratories (Horst, the Netherlands) were each injected with 1
x 107 canine prostatic carcinoma cells (ACE-1) subcutaneously in both flanks 
under sedation to induce tumours. When the tumours were approximately 5 
mm in diameter, each tumour was injected 105 pfu of vvdd-luc or placebo 
(PBS), and the injection was repeated in 10 days. The size of the tumours was 
measured in two dimensions three times a week, and the mice were euthanized 
when the sum of the longest diameter of both tumours was 25 mm or the 
tumours became ulcerated. The schematic drawing of the xenograft model is 
presented in Figure 6.
Experimental xenograft model in nude female mice. Ten million ACE-1 cells 
were injected subcutaneously in both flanks in each mouse. Mice were treated twice within 10 
days with oncolytic vaccinia virus or placebo. vvdd-luc, lucifarese-expressing double-deleted 
oncolytic vaccinia virus; pfu, plaque-forming units.
4.4.3 POST-MORTEM EXAMINATION, HISTOLOGY AND 
IMMUNOHISTOLOGY (I)
The heart, lung, liver, spleen, kidney, and all tumours from ACE-1 xenograft 
mice were collected for histological examination. Tissues were fixed in 10% 
KA 2010 
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buffered formalin, routinely paraffin wax-embedded, cut in tissue sections of 
3-5 μm and stained with HE or immunohistological stains. 
Immunohistology was used to visualize virus infection and apoptotic cells
by using a rabbit anti-vaccinia antibody (Quartett, Berlin, Germany), a rabbit 
anti-?-galactosidase antibody (EMD Millipore Corp., Temecula, CA, USA), 
and a rabbit anti-cleaved caspase-3 antibody (Cell Signaling Technology, Inc., 
Danvers, MA, USA). 
The Lab Vision™ Biotinylated Goat anti-Rabbit HRP kit (Thermo Fisher 
Scientific, Runcorn, UK) was used as the detection system. Staining was 
visualized with 3,3’-diaminobenzidine (DAB) or Polydetector HRP Green 
Substrate-Chromogen kit (Bio SB Inc., Santa Barbara, CA, USA) with Harris 
haematoxylin counterstaining. The vvdd-luc-infected D17 cell line served as a 
positive control and sections without primary antibody and tumours of the 
untreated mice as negative controls.
4.4.4 FUNCTIONALITY OF HUMAN CD40L IN DOGS (I)
Canine peripheral blood mononuclear cells (PBMCs) were collected from left-
over buffy coat from volunteer blood donors after separation of red blood cells 
and plasma in the Canine Blood Bank, Veterinary Teaching Hospital of the 
University of Helsinki following a previously described protocol (Schreuer & 
Hammerberg 1996). 
A549 cells were infected with Ad5/3-hTERT-CD40L, and the control was 
Ad5/3-hTERT. The supernatant was collected and filtered to purify CD40L 
produced by the virus. Canine PBMCs were cultured with the filtered 
supernatant in Roswell Park Memorial Institute (RPMI) medium (Lonza). IL-
8 was measured by ELISA (Canine CXCL8/IL-8 Quantikine, R&D Systems, 
Minneapolis, MN, USA) following the manufacturer’s instructions at 24, 48, 
72 and 96 h after co-culture.
4.4.5 BIOPSY TRANSDUCTION ASSAY (I)
Fresh biopsy samples of naturally occurring suspected tumours in pet dogs 
were collected during surgery or after euthanasia in 10% FCS DMEM with 1% 
L-glutamine and 2% P-S. The study protocol was approved by the Ethics
Committee of the Campus of Viikki, University of Helsinki, Finland, and all 
owners signed informed consent forms. 
Biopsy samples were sliced into 2 x 2 x 2 mm pieces, and three pieces from 
each were transferred into one well in 24-well plates. Each well was infected 
with 5 x 106 pfu of vvdd-hCD40L-tdTomato, and the samples were incubated 
in 5% CO2 at 37°C. Transduction of tdTomato was observed by fluorescence 
microscope (Olympus 1X71 inverted microscope, Olympus) at 1, 2 and 4 days 
after infection.
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4.4.6 DOG MODELS (III, IV)
4.4.6.1 Dogs (III, IV)
Two healthy adult male HsdRcc:DOBE Beagle dogs were used for the vaccinia 
experiment, and two females of the same breed were used in the SFV 
experiment. The dogs were purchased from Harlan Laboratories (Gannat, 
France).
4.4.6.2 Study design (III, IV)
Dog 1 in the vaccinia virus experiment (III) (dog VV1) was used for the 
evaluation of acute toxicity and received a single infusion of vvdd-tdTomato-
CD40L. Dog 2 in the vaccinia virus experiment (dog VV2) was used to evaluate 
chronic toxicity and received four infusions of vvdd-tdTomato-CD40L once a
week. Dog VV1 was euthanized 24 h after virus infusion and dog VV2 one week 
after the 4th virus infusion. The dogs were randomly chosen for each group.
Dogs 1 and 2 in the Semliki Forest virus experiment (IV) (dog SFV1 and 
SFV2) received one infusion of SFV and were euthanized 3 weeks later. All 
dogs had full necropsy performed by a study pathologist. The study plan and 
virus doses are presented in Table 6.
The dose of the VV (III) was based on the phase I dose escalation study with 
another oncolytic VV, JX-594, in patients with primary or metastatic liver 
cancer (Park et al. 2008).  The highest dose in the study was 3 x 109 pfu per 
injection, which is approximately 4 x 107 TCID50/kg in a 75-kg patient 
assuming that pfu and TCID50 units are roughly equivalent. The dose we chose 
to use in our study was 1.2 x 108 TCID50/kg, which is three times the maximum 
dose used in human patients (Park et al. 2008).
In the SFV study, we used a low dose, injecting both dogs with 106 pfu. In 
mice, guinea pigs and rabbits, commonly used doses are between 104 and 106
pfu, and in a susceptible mammalian host, attenuated SFV may reach peak 
titres of up to 108 pfu/ml, even following a minute inoculum. The size of the 
animal does not seem to matter for the penetrance of viraemia (Bradish et al. 
1971, Bradish & Allner 1972, Fleming 1977, Jagelman et al. 1978, Fazakerley et 
al. 1993).
The virus was diluted in 50 ml of saline (Baxter, Norfolk, UK) and was 
given over 15 min (200 ml/h) as an intravenous infusion into a peripheral vein.
The SFV infusion line ran through a tempered water bath (ca. 37°C) before 
entering the vein (IV). Before virus administration, an intravenous catheter 
was placed and 10 ml of saline was administered through it to ensure vein 
access. The saline bag and infusion line were flushed with 25 ml of saline at 
the same infusion rate after virus administration to confirm that the intended 
virus dose was delivered. In all, the infusion lasted approximately 23 min.
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In the SFV study, we simulated the virus administration protocol 
afterwards to confirm that the dogs received live virus. The virus diluted in
saline was kept on ice for 3 h 25 min, which was the maximum time from virus 
preparation until it was delivered, and then directed at the infusion speed 
through a 37°C water bath. The outcoming solution was collected for virus 
titrating.
The dogs were monitored for adverse events according to the Veterinary 
cooperative oncology group - Common terminology criteria for adverse events 
(VCOG-CTCAE) (Veterinary cooperative oncology group 2004). The 
monitoring schedule is shown in Table 7.
Table 6 Study plan and virus doses of the dogs receiving oncolytic vaccinia or 
Semliki Forest virus.
Dog
Dose
no.
Dose
(TCID50 or 
pfu/kg)
Weight
(kg) Total dose
Administration 
schedule
Endpoint/
Euthanasia
VV1 1 1.2 x 108 12.8 4 x 109 TCID50 Single infusion 24 h p.i.
VV2 1
2-4
1.2 x 108
0.8 x 108
14.0 1.7 x 109 TCID50
1.1 x 109 TCID50
Infusions once 
per week over 4
weekstimes
1 wk after 4th
virus infusion
SFV1 1 ~1.5 x 105 6.7 106 pfu Single infusion 3 wk p.i.
SFV2 1 ~7.8 x 104 12.9 106 pfu Single infusion 3 wk p.i.
VV1, Dog 1 in vaccinia experiment; VV2, Dog 2 in vaccinia experiment; SFV1, Dog 1 in Semliki 
Forest virus experiment; SFV2, Dog 2 in Semliki Forest virus experiment
p.i. post-infusion
Table 7 Clinical examination schedule of the dogs receiving oncolytic vaccinia or 
Semliki Forest virus during the first 24 hours after virus administration.
Time RR HR MM CRT T BP Swelling Itching Vomiting
0 x x x x x x x x x
15 min x x x x x x x x x
30 min x x x x x x x x x
45 min x x x x x x x x x
1 h p.i. x x x x x x x x x
2 h p.i. x x x x x x x x x
4 h p.i. x x x x x x x x x
8 h p.i. x x x x x x x x x
11 h p.i. x x x x x x x x x
24 h p.i x x x x x x x x x
RR, respiratory rate; HR, heart rate; MM, colour of mucous membranes; CRT, capillary refill time; 
T, rectal temperature; BP, blood pressure: systolic/diastolic/mean
p.i. post-infusion
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4.4.6.3 Sample collection for clinical pathology (III, IV)
Blood was collected from the jugular, cephalic or saphenous vein for 
haematology into tubes containing potassium (K2) EDTA, and for clinical 
chemistry and neutralizing antibody measurements into serum tubes 
according to Table 8A (III) and 8B (IV).
Table 8 Sample collection schedule for the study of dogs receiving (A) oncolytic 
vaccinia (III) or (B) Semliki Forest virus (IV).
  A.
Week Day Laboratory measurements Comments
1 0 CBC, chem, NAbs, urinalysis, blood, saliva, urine, 
faeces
Virus infusion
1 CBC, blood, saliva, urine, faeces Euthanasia dog VV1
2 CBC, blood, saliva, urine, faeces 
4 CBC, blood, saliva, urine, faeces 
2 7 CBC, chem, Nab, urinalysis, virus
9 CBC, blood, saliva, urine, faeces 
11 CBC, blood, saliva, urine, faeces 
3 14 CBC, chem, NAbs, urinalysis, blood, saliva, urine, 
faeces 
16 CBC, blood, saliva, urine, faeces 
18 CBC, blood, saliva, urine, faeces 
4 21 CBC, chem, NAbs, urinalysis, blood, saliva, urine, 
faeces
23 CBC, blood, saliva, urine, faeces 
25 CBC, blood, saliva, urine, faeces 
5 28 CBC, chem, NAbs, urinalysis, blood, saliva, urine, 
faeces
Euthanasia dog VV2
  B.
Week Day Laboratory measurements Comments
1 0 CBC, chem, NAbs, urinalysis, blood, urine, faeces Virus infusion
1 CBC
2 CBC, blood, urine, faeces 
4 CBC, blood, urine, faeces 
2 7 CBC, chem, urinalysis, blood, urine, faeces
9 CBC, NAbs, blood, urine, faeces 
11 CBC
3 14 CBC, chem, urinalysis, blood, urine, faeces 
16 CBC
18 CBC
4 21 CBC, chem, NAbs, urinalysis, blood, urine, faeces Euthanasia SFV dogs
CBC, complete blood count; Chem, clinical chemistry; NAbs, neutralizing antibodies; Blood, saliva, 
urine, faeces; for virus detection
VV1, Dog 1 in vaccinia experiment; VV2, Dog 2 in vaccinia experiment; SFV, Semliki forest virus 
dogs
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Table 9 Haematology and clinical chemistry parameters.
Haematology
Red blood cell count (RBC) Leukocytes (Leuk)
Mean cell volume (MCV) Differential count
Haematocrit (HCT) Neutrophil (Neu)
Red cell distribution width (RDW) Lymphocyte (Lym)
Haemoglobin (HGB) Monocyte (Mon)
Mean cell haemoglobin (MCH) Eosinophil (Eos)
Mean cell haemoglobin concentration (MCHC) Basophil (Bas)
Platelet count (PLT) Large unstained cell (LUC)
Clinical chemistry
Alanine aminotransferase (ALT) Glucose
Albumin Phosphate
Alkaline phosphatase (ALP) Potassium
Bilirubin total Protein
Calcium Sodium
Cholesterol Urea
Creatinine
Haematology was analysed by an automated haematology analyser (ADVIA 
2120i Hematology System, Siemens Healthcare Diagnostics Inc., Tarrytown, 
NY, US). Serum was separated after a minimum 30-min incubation at room 
temperature by centrifuging for 10 min at 2400 G and analysed by a clinical 
chemistry analyser (Konelab 30i, ThermoFisher Scientific, Vantaa, Finland). 
Table 9 shows the haematology and clinical chemistry parameters measured.
4.4.6.4 Sample collection for virus detection and cytokines (III, IV)
In the vaccinia experiment (III), three millilitres of blood was collected into 
EDTA tubes for virus detection and cytokine measurements before and 
immediately after virus administration, and then 1, 2, 4, 8, 11 and 24 h and 2, 
4 and 7 days after each virus infusion. 
In the SFV experiment (IV), four millilitres of blood was collected into 
serum tubes for virus detection before and 2, 4 and 22 h and 2, 4, 7, 9, 14 and 
21 days after virus infusion. 
Saliva for the vaccinia virus experiment (III) was collected by holding two 
cotton tips in each side of the mouth for 30 s. Five millilitres of urine was 
collected by cystocentesis for each sample, and 10-15 g of faeces was collected 
rectally or from the kennels when fresh not contaminated sample was available 
and the rectum contained no faeces (III, IV). The collection schedule is 
presented in Table 8A (III) and 8B (IV).
Blood samples for vaccinia virus detection (III) were frozen first at -18°C 
and transferred the same day to -80°C until analysis. Serum for SFV detection 
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(IV) was separated as described above, and all samples were frozen and stored 
following the same protocol as for the samples for vaccinia virus detection.
4.4.6.5 qPCR for vaccinia virus (III)
Gentra Puregene Blood Kit (QIAGEN, Germantown, MD, USA) was used to 
extract DNA from whole blood following the manufacturer’s instructions. 
Saliva collected by cotton swabs was diluted in 2500 μl of phosphate-buffered 
saline (PBS, BioWhittaker, Lonza), then the sample was shaken and the cotton 
swabs were squeezed towards the tube walls to get all of the fluid into the tube. 
Gentra Puregene Blood Kit for Body Fluids (QIAGEN) was used for DNA 
extraction according to the manufacturer’s instructions using 1 ml of diluted 
saliva. DNA from urine was extracted by the same method, using 1 ml of urine,
and for faeces, 180-220 mg. Faecal samples were first handled by QIAamp 
DNA Stool kit (QIAGEN GmbH, Hilden, Germany) by using Buffer ASL and 
InhibitEX tablets to lyse bacteria and other pathogens and to absorb 
inhibitors, and then Gentra Puregene Tissue Kit (QIAGEN) was used 
according to the manufacturer’s instructions. The same kit was used for 
necropsy samples using 50-100 mg of each tissue. Finally, extracted DNA 
concentration was measured by spectrophotometry (Nanodrop 8000, Thermo 
Scientific, Wilmington, DE, USA). To quantify the method, we used samples 
from healthy dogs as negative controls, and for positive controls the same 
samples were spiked with VV. Collection of saliva, urine and faeces for qPCR 
is presented in Figure 7.
Collection of saliva, urine and faeces for vaccinia qPCR in Study III. PBS, 
phosphate-buffered saline.
KA 2013 
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Table 10 Primers and probes used in vaccinia virus qPCR.
Gene target Name Sequence
HA J7R OPHA-probe AGT GCT TGG TAT AAG GAG
OPHA-F89 GAT GAT GCA ACT CTA TCA TGT A
OPHA-R219 GTA TAA TTA TCA AAA TAC AAG ACG TC
Canine actin Probe TCC TGG CCT CAC TGT CCA CCT TCC AGC
FW GCG CAA GTA CTC TGT GTG GAT
RW GTC GTA CTC CTG CTT GCT GAT
Table 11 Limit of detection and quantification for vaccinia genome qPCR.
Secretion Detection limit Quantification limit
Whole blood 1 copy/30 μl 1 copy/3 ml
Urine 1 copy/100 μl 1 copy/10 ml 
Faeces 1 copy/5 mg 1 copy/500 mg
Saliva NA NA
NA, not available
Polymerase chain reaction (PCR) was based on primers and probe 
targeting the HA J7R gene (Applied Biosystems UK, Cheshire, UK). Ten 
microlitres of extracted DNA, 12.5 μl of 2X LightCycler 480 Probes Master Mix 
(Roche, Mannheim, Germany), 0.25 μl of each 50 μM primer, 0.4 μl of 0.1 μM 
probe and 0.16 μl of nuclease-free water were used for each qPCR reaction.
Quantitative PCR (qPCR) was performed by LightCycler 480 II (Roche 
Diagnostics GmbH, Mannheim, Germany) under the following conditions: 2 
min at 50°C, 10 min at 95°C,  50 cycles of  15 s at 95°C and 1 min at 60°C and
10 min at 40°C. All samples were run in triplicate. A standard curve was 
created for absolute quantification by using HA-vaccinia plasmid kindly 
donated by Professor Olli Vapalahti, Haartman Institute, University of 
Helsinki.  Water was used as a negative control. In addition, TaqMan 
Exogenous internal positive control (Applied Biosystems, Life Technologies 
Corporation, Carlsbad, CA, USA) was used to ensure that there were no PCR 
inhibitors. Standard curve and qPCR reaction were run with the same protocol
????????????-actin to quantify the result for canine genomic DNA. Probes and 
primers were purchased from Oligomer (Helsinki, Finland) and are presented 
in Table 10. The limit of detection and quantification for analysis are shown 
in Table 11. We were unable to define limits for DNA detection or saliva 
quantification since the amount of saliva in the sample was low.
4.4.6.6 Detection of infectious virus (III, IV)
Plaque assay was performed for all saliva and urine samples positive for 
vaccinia DNA and for selected blood samples to detect infective virus (III). 
Four hundred thousand A549 and Vero cells per well were plated on a 6-well 
plate in GM with 10% FCS. The cells were incubated for 24 h and then infected 
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with 200 μl of sample diluted with 6 ml of growth media (1 ml/well). To 
maximize infection, infected cells were centrifuged at 600 g for 20 min at room 
temperature and then incubated for 30 min in 5% CO2 at 37°C. GM with 10% 
FCS was then added, and the plates were incubated for 3 days. Transduction 
was detected with fluorescence microscope on days 1 and 3, and plaques were 
stained with Coomassie blue on day 3.  
PBS and the baseline samples from the Beagles taken before virus infusion 
served as negative controls. Positive controls included blood, saliva and urine 
from healthy dogs and PBS in which virus was added right before infection. 
In addition, TCID50 with 10-2-10-9 dilutions was performed on selected 
blood samples in Vero cells. The results were read on day 10.  
In the SFV experiment (IV), saline containing virus used to simulate virus 
administration protocol and sera collected from the dogs were titrated for SFV 
A7(74) on Vero cells according to a previously published protocol
(Ruotsalainen et al. 2014). Serial dilutions of samples were prepared in cold 
medium, and the stock A7(74) virus served as a positive control.
The protocol for virus titration from urine and faecal samples was modified 
from Buonagurio et al. (1999) (IV). Urine samples were diluted 1:10 and 1:100 
in DMEM with 1 g/l glucose and virus titration was done on Vero cells as for 
sera. Faeces (0.1-0.2 g) were mixed with 10x (w/v) DMEM and centrifuged at 
3000 g for 10 min at 4°C before virus titration. The supernatant was diluted in 
growth media 1:10 and 1:100 for titration after sterile filtering with a 0.22 μm 
PES membrane syringe filter (Syringe Filter, Porvair Science, Leatherhead, 
UK). Baseline samples and growth media served as negative controls. Faecal 
samples for recovery controls were prepared by adding 106 pfu of SFV A7(74) 
per 0.1 g of baseline faecal samples of both dogs diluted in 10x (w/v) amount 
of medium. After that, the mixtures were vortexed, sterile-filtered, serial-
diluted (from 10-1 to 10-6) to growth medium and titrated as described above.
4.4.6.7 Cytokine measurement (III)
Cytokines were measured from the plasma collected from EDTA tubes by 
using Procarta Immunoassay Magnetic Bead kits (Affymetrix Panomix, Santa 
Clara, CA, USA) and are presented in Table 12. To eliminate infectious virus
before analysis, 50 μl of QuantiGene Plex Assay Kit Lysis Mixture (Affymetrix 
Panomix) was added to 100 μl of plasma. Fluorescence was measured by a Bio-
Plex 200 System (Bio Rad, Hercules, CA, USA) device according to the
manufacturer’s instructions.
4.4.6.1 Neutralizing antibodies (III, IV)
NAbs for VV virus (III) were measured from the serum samples from dog VV2 
collected 2, 3 and 4 weeks after first virus infusion and in dogs receiving SFV 
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Table 12 Cytokines measured from the Beagles receiving vaccinia virus.
Cytokine Abbreviation Function
????????????? IFN-? Immunostimulatory and immunomodulatory 
effects, Inhibit viral replication directly, promote 
apoptosis in infected cells
Interleukin-2 IL-2 Growth, proliferation and differentiation of T cells
Interleukin-6 IL-6 Pro-inflammatory, recruit lymphs & neuts; induced 
by vaccinia early gene products
Interleukin-8 IL-8 Neutrophil chemotactic factor: migrate toward the 
site of infection + phagocytosis
Interleukin-10 IL-10 Anti-inflammatory
Interleukin-12 IL-12 T cell stimulation
Tumour necrosis factor-
?
TNF- ? Pro-inflammatory, recruit lymphs & neuts; induced 
by vaccinia early gene products
Monocyte chemotactic 
protein-1
MCP-1 Chemotactic factor for monocytes 
Lymphs, lymphocytes; neuts, neutrophils
(IV)  from samples collected 2, 9 and 21 days after virus infusion (Table 8A
and B). 
For VV NAb measurement (III), 50 000 A549 were plated per well in 
DMEM with 10% FCS on a 96-well plate. To inactivate complement, serum 
was heated the next day for 90 min at 56°C, and dilution serial of 1:4 was 
prepared in plain DMEM. Diluted serum and 48 pfu of vvdd-luc at a 
concentration of 4 x 103 pfu/ml were incubated for 60 min at room 
temperature on a shaker with a slow rate.
GM was then removed and the cells were washed, after which 100 pfu of 
vvdd-luc incubated in serum dilutions was added in triplicate to each well. 
After incubation for 60 min in 5% CO2 at 37°C, 100 μl of DMEM with 10% FCS 
was added to the wells, and the plates were incubated for 20 h in 5% CO2 at 
37°C. GM was then removed, cells were lysed and luciferase activity measured 
with Luciferase Assay System (Promega) using TopCount luminometer 
(PerkinElmer, Waltham, MA, USA) according to the manufacturer’s 
instructions. The NAb titre for VV was defined as the highest dilution of the 
???????????????????????????????????????????????????(Mastrangelo et al. 1999).
SFV NAbs were measured according to Ruotsalainen et al. (2012). In brief, 
the serum samples were diluted 1/2, 1/5, 1/25, 1/125, 1/625 and 1/3125 into 
DMEM, and mixed with 50 pfu of the A7(74) virus in 1:1 (100 μl:100 μl). The 
mixture was incubated on ice for approximately 30 min and then plaque was 
titrated on Vero cells in 12-well plates in duplicate. DMEM was used as a 
negative control and polyclonal rabbit anti-SFV antibody in DMEM as a 
positive control. Fluorescence was monitored by fluorescence microscope 
(Zeiss Axio Observer Z1). The highest dilution of the virus that completely 
prevented plaque formation (50 pfu SFV A7(74)) was defined as the NAb titre.
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4.4.6.2 Necropsy (III, IV)
Complete necropsy was performed on all dogs by a board-certified study 
pathologist. Samples for histological evaluation were collected from the tissues 
listed in Table 13. Tissues were fixed in neutral-buffered 10% formalin, 
trimmed, embedded in paraffin, sectioned at 4 μm thickness, routinely 
processed and stained with HE.
Samples from the same organs were collected in liquid nitrogen for 
detection of the virus by qPCR in the vaccinia study (III), whereas only selected 
organs were collected in dry ice in the SFV experiment (IV) (Table 14). In 
addition, in the VV study (III) tissue samples were collected for TEM 
examination and were fixed in 5% glutaraldehyde in 0.1 M sodium cacodylate 
buffer (pH 7.2-7.4).
Table 13 Tissue list for histopathology collection from the dogs receiving oncolytic 
vaccinia (VV)(III) and Semliki Forest virus (SFV) (IV). Abbreviations in parentheses mean that 
tissue was collected only in that study. 
Adrenal Glands (cortex and medulla) Macroscopic Lesions
Aorta (thoracic) (VV) Optic Nerves
Bone and Joint (distal femur) Ovaries (SFV)
Bone Marrow (rib) Pancreas
Brain* Peripheral Nerve (sciatic)
Caecum (VV) Pituitary Gland
Colon (VV) Salivary Gland (submandibular)
Duodenum (VV) Skeletal Muscle (thigh)
Oesophagus (VV) Skeletal Muscle (diaphragm)
Eyes (VV) Skin (VV)
Gallbladder (VV) Spinal Cord (cervical and lumbar)
Gut-associated lymphoid tissue Spleen
Heart Stomach (cardiac, fundic and pyloric) (VV)
Ileum (VV) Testes (VV)
Injection Site (dosing sites only) (VV) Thymus
Jejunum Thyroid/Parathyroid Glands
Kidneys Tongue (VV)
Liver Trachea (VV)
Lungs Urinary Bladder (VV)
Lymph Nodes, mandibular Uterus (SFV)
Lymph Nodes, mesenteric Vagina (SFV)
* For SFV: hippocampus, cortex, corpus callosum, cerebellum and pons
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Table 14 Tissue collected for Semliki Forest virus immunohistochemistry (IV).
Brain: hippocampus Liver
Brain: cortex Lymph Nodes, mandibular
Brain: corpus callosum Lymph Nodes, mesenteric
Brain: cerebellum Skeletal Muscle (thigh)
Brain: pons Spinal Cord, cervical
Kidneys Spleen
4.5 STATISTICS
Statistical analysis for virus transduction, oncolytic potency and the xenograft 
model were performed with Microsoft Office Excel 2010 (Microsoft, 
Redmond, WA, USA), GraphPrism software (GraphPad Software Inc., La 
Jolla, CA, USA) and SAS 9.2 (SAS Institute Inc., Cary, NC, USA), and the 
results are shown as means and standard deviation (I). The oncolytic potency 
of the viruses in each cell line was analysed separately with analysis of variance 
(ANOVA) for repeated measurements.
The analysis of SCCF1 virus production was performed with GraphPrism 
software and is presented as means and standard error of means (II). 
Differences in the viability of cells were calculated using Student’s t-test for 
two independent samples with GraphPrism software (GraphPad Software Inc.,
La Jolla, CA, USA) (II).
Viability of SFV-infected cells was analysed with GraphPad Prism software,
and results are shown as means and standard deviation (IV). Statistical 
analysis was performed using unpaired, two-tailed t-test.
Tumour volume was calculated as follows: 0.52 x longest diameter x 
shortest diameter2. The mean volume of both tumours of each mouse was used 
for calculations (I). ANOVA for repeated measurements was used, and the 
baseline value was considered as a covariate and day, treatment and their 
interaction as fixed effects. Log-transformation of the outcome variable was 
used to reach normality.
For all statistical tests, P<0.05 was considered significant. For dog 
experiments, only descriptive statistics were used (III, IV).
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5 RESULTS
5.1 IN VITRO STUDIES
5.1.1 TRANSDUCTION AND CYTOTOXICITY (I, II, IV)
Transduction of luciferace was detected in all cell lines, including the canine 
normal kidney cell line, even with low dosages, confirming that vvdd-luc was 
able to enter, infect and induce early gene expression in all examined cell lines 
(Figure 8). In addition, transduction of tdTomato by vvdd-tdTomato was also 
detected in all cell lines (Figure 9).
Vvdd-tdTomato and vvdd-CD40L-tdTomato both effectively killed all 
canine cell lines (Figure 10), but at lower viral doses oncolytic potency of 
vvdd-tdTomato was significantly better in D17 (0.01 and 0.1 pfu/cell: 
P<0.001), ACE-1 (0.01 pfu/cell: P=0.0001; 0.1 pfu/cell: P<0.001) and MDCK 
cells (0.01 pfu/cell: P<0.001). No difference was detected in Abrams cells 
(P=0.1128). Both viruses killed more cells over time, although vvdd-tdTomato-
induced oncolysis was significantly more effective than vvdd-hCD40L-
tdTomato-induced oncolysis in D17 (0.1 pfu/cell at 72, P<0.0001 and 96 h, 
P<0.0001; 1 pfu/cell at 24 h, P=0.0022) and ACE-1 cells (0.1 pfu/cell at 94 h, 
P=0.0007 and 1 pfu/cell at 24 h, P=0.0014). 
Luciferase transduction of vvdd-luc in canine and feline cell lines. Cells were 
infected with vvdd-luc with different virus doses in triplicate and luminance of luciferase was 
measured 4 h after infection in relative light units (RLUs). Values are presented as means. 
Abrams and D17, canine oseteosarcoma cell lines; ACE-1, canine prostatic carcinoma cell line; 
MDCK, canine kidney cell line; SCCF1, feline squamous cell carcinoma cell line; pfu, plaque-
forming units; error bars, standard deviation.
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Transduction of vvdd-hCD40L-tdTomato after standard plaque assay by 
fluorescence microscope detecting tdTomato at 24 h. D17 cells were infected with different 
doses of vvdd-luc (A:0.04, B: 0.2, C: 1 and D: 5 pfu/cell), ACE-1 0.2 (E), D17 (F), MDCK (G) and 
SCCF1 with 5 pfu/cell (H). Scale bar = 200 μm.
Interestingly, vvdd was unable to effectively lyse SCCF1 cells when 0.01 0r 
0.1 pfu/cell was used, and cytotoxicity was significantly more effective 
(P=0.0073) in A549 cells than in SCCF1 cells at the dose of 1 pfu/cell and when 
viability was measured on day 3. When SCCF1 was growing as an intact 
monolayer, the cells stayed alive up to 10 days and only a high dose (100 
pfu/cell) of vvdd-luc was able to effectively kill the cells. UV-inactivated vvdd 
had no effect on the viability of SCCF1 cells (Study II: Figure 1).
Attenuated SFV VA7-EGFP was also able to infect both tested canine 
osteosarcoma cell lines, and fluorescence of EGFP was detected in both cell 
lines (Figure 11). The virus replicated at a slightly higher rate in Abrams cells 
than in D17 cells and induced a more rapid and pronounced cell kill within 48 
h (Abrams: 0 vs. 0.01, 0.1 and 1 pfu, P<0.001 in all and D17: P=0.0053, 0.008 
and 0007, respectively).
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Cell killing efficacy of vvdd-tdTomato (A) and vvdd-hCD40L-tdTomato (B) in 
canine and feline cell lines 94 h after virus infection with different virus doses. Cells were 
infected in triplicate, and values are presented as means and standard deviation. Abrams and 
D17, canine oseteosarcoma cell lines; ACE-1, canine prostatic carcinoma cell line; MDCK, 
canine kidney cell line; SCCF1, feline squamous cell carcinoma cell line; pfu, plaque-forming 
units; error bars, standard deviation.
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Transduction and oncolysis of VA7-EGFP in canine osteosarcoma cell lines, 
Abrams and D17.  Cells were infected with MOI 1, MOI 0.1 or MOI 0.01 in triplicate (one replica 
per sample type presented) and infection was monitored by fluorescence microscopy at 24 and 
48 h after infection. Green colour indicates gene transfer and virus infection. Cytopathic effect 
was confirmed by crystal violet staining at 48 h after infection and is seen as loss of the stain. 
MOI, multiplicity of infection; p.i., post-infection. Scale bar 200 μm.
Results
69
Virus production of vvdd-tdTomato (A) and vvdd-hCD40L-tdTomato (B) over 
time in canine and feline cell lines. Two hundred thousand cells were infected in triplicate with 
the virus at 0.01 pfu/cell, and plaque forming test was performed to determine the amount of 
infectious virus. Values are presented as means and standard deviation. Abrams and D17, 
canine oseteosarcoma cell lines; ACE-1, canine prostatic carcinoma cell line; MDCK, canine 
kidney cell line; SCCF1, feline squamous cell carcinoma cell line; pfu, plaque-forming units.
-
-
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5.1.2 VIRAL REPLICATION AND CLONAL ASSAY (I, II)
Viral replication varied significantly in different cell lines over time (Figure
12). The highest amount of infectious virus was recovered from ACE-1 cells at 
96 h (1 420 000 pfu), whereas the lowest amount was found in SCCF1 cells and 
it was approximately the same at all time-points (~300-400 pfu). Virus 
recovery decreased in osteosarcoma cell lines after 48 h. 
Clonal assay was performed in ACE-1 and SCCF1 cell lines since they were 
more resistant to oncolysis caused by vvdd (Table 15, Figure 13). Infected 
ACE-1 cells were able to form cell colonies one day after infection when 10 000 
or 1000 cells were plated, but only a few colonies were detected when 10 000 
cells were plated 3 days after infection. 
SCCF1 was more resistant to the killing effect of vvdd. Cell colonies were 
detected in all samples when cells were collected one day after infection, except 
when 10 infected cells were plated. Relative to the negative control,
approximately 50% fewer cell colonies were identified when 1000 cells were 
plated 3 days after infection. The difference was smaller when less cells were 
used.
Table 15 Clonality assay. ACE-1and SCCF1 cells were infected with vvdd-tdTomato or 
vvdd-hCD40L-tdTomato 10 pfu/cell in duplicate and 10 000, 1000, 100 or 10 infected cells were 
grown 1 or 3 days to evaluate whether cells would form colonies. Values are shown as means.
Cell line  Virus Number of cells plated
Time 10 100 1000 10 000
ACE-1 Number of cell colonies
Day 1 Mock 1.9 7.9 34.9 NE
vvdd-tdTomato 0 0 2.1 8.2
vvdd-CD40L-tdTomato 0 0 0.3 17.8
Day 3 Mock 8.2 67.4 NE NE
vvdd-tdTomato 0 0 0 0.5
vvdd-CD40L-
tdTomomato 0 0 0 0.2
SCCF1 Number of cell colonies
Day 1 Mock 4.0 29 159 NE
vvdd-tdTomato 0 3.3 43.3 NE
vvdd-CD40L-
tdTomomato 1.4 5 131.5
NE
Day 3 Mock 2.1 10.6 187 NE
vvdd-tdTomato 1.5 7.5 102 NE
vvdd-CD40L-tdTomato 1.0 7.0 107.9 NE
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Cell colony formation of vvdd-infected feline squamous carcinoma cells, 
(SCCF1). A. placebo wells. B. vvdd-infected cells. SCCF1 cells were infected in duplicate with 
vvdd-tdTomato at 10 pfu/cell, after which infected cells were collected, plated on 6-well plates 
(10, 100, 1000 or 10 000 cells/well; the amount of cells is on the left side of the wells) and 
cultured for 24 hours to evaluate whether they would form colonies. Colonies were visualized by
crystal violet staining before counting.
5.1.3 QUANTIFICATION AND INFECTIVITY OF THE PRODUCED 
VIRIONS IN VITRO (II)
Titrating of supernatants from chronically infected confluent SCCF1 cell 
cultures showed low but persistent production of the virus for up to 12 days 
after infection. The produced virions were able to re-infect both SCCF1 and 
A549 cells, suggesting that the secreted virions retain their infectious capacity. 
Neutralization assay used to further evaluate the characteristics of the virions 
confirmed that anti-vaccinia antibody recognized and neutralized almost all of 
the particles (Study II: Figure 2).
5.1.4 ABNORMAL MORPHOLOGY OF VACCINIA VIRIONS SECRETED 
BY SCCF1 CELLS (II)
Virions produced by SCCF1 and A549 cells differed from each other when 
examined under EM. A549 cells produced brick-shaped virions surrounded by 
an outer envelope, which are typical characteristics for a mature, enveloped 
VV. Contrary to this, the virions manufactured in SCCF1 cells were immature 
and misshapen and lacked the outer envelope. In addition, the particles had
irregular surface and staining intensity, and they were loosely packed (Study
II: Figure 3).
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5.1.5 ULTRASTRUCTURE OF VIRAL PARTICLES WITHIN INFECTED 
CELLS (II)
EM results from thin sections of vaccinia-infected cells were in line with those 
of negative-stained whole-mount viral particles. 
In A549 cells, numerous viral particles of different maturation stages were 
visible at low magnification. Mature virus (MV) was the most common virion 
type, the majority being either wrapped virions (WVs) or intracellular 
enveloped virions (IEVs) enfolded by trans-Golgi cistern membrane. 
Extracellular enveloped virions (EEVs) were found outside the cells and were 
surrounded by two membranes, one of which was constructed from the cell 
plasma membrane. EEVs, which were still in contact with cells, were also 
detected and recognized as cell-associated extracellular enveloped virus
(CEV). At higher magnification, clear membrane layers were visualized. The 
viral factory, where early replication takes place, was also recognized as a low-
to-middle electron density zone in the juxta-nuclear area, where other cellular 
organelles were missing. IEVs and WVs were detected around the viral factory
(Study II: Figure 4).
In SCCF1 cells, the replication factory was not clearly visible and contained 
abnormal granular virosome. Only a few immature viruses (IVs) of different 
size and some immature virion with nucleoids (IVNs) were recognized.
Enlarged IVs without a membranous envelope were visualized in the 
peripheral area, where viruses are normally released outside the cell, and EEVs 
were not seen at all (Study II: Figure 5).
5.1.6 CELL DEATH TYPE ASSESSMENT
When D17 osteosarcoma cells were infected with vvdd, multiple dying cells 
were detected in the samples 24 and 48 h after infection. Dying cells had 
changes characteristic for apoptosis, as recently reported in cells killed by 
oncolytic viruses (Whilding et al. 2013). Expression of the activated executor 
caspase-3 by immunohistology and TEM confirmed the findings (Study III, 
Figure 4).
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5.2 IN VIVO STUDIES
5.2.1 MOUSE XENOGRAFT MODEL
The oncolytic effect of vvdd-luc was confirmed by a significant delay
(P=0.046) in tumour progression in the ACE-1 xenograft model in nude mice 
(Figure 14). 
In virus-treated tumors, histological evaluation revealed multiple regions 
suggestive of necrosis since no viable cells were seen. A few poxvirus-like 
cytoplasmic inclusion bodies were identified in degenerating cells around the 
necrotic areas. Pronounced stroma formation was also visualized in tumours. 
Other organs examined in necropsy did not reveal any pathological changes.
The presence of vaccinia virus in the tumours was shown by 
immunohistology; anti-vaccinia and anti-?-galactosidase antibodies were 
detected in the cytoplasm of both dead and viable tumour cells in the necrotic 
areas and their surrounding regions (Study III, Figure 6). Staining with the 
anti-vaccinia antibody was more pronounced than with the anti-?-
galactosidase antibody, and in one tumour (left tumour in mouse 1 in the virus-
treated group) it was not present. Virus was not found in any examined organs 
by immunohistology.
Oncolytic potency of vvdd-luc in canine ACE-1 prostate cancer tumours in 
mice. Six mice were injected with 1x107 ACE-1 cells subcutaneously. Vvdd-luc was injected 
intratumourally twice (arrows) at a dose of 1x105 pfu (dashed line) in three mice, and three other 
mice received the same volume of phosphate-buffered saline. The anti-tumoural response was 
evaluated by measuring tumour size. The tumour size differed significantly (P=0.046) between 
the virus and control groups (asterisk). Values are presented as means and standard deviation.
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Production of interleukin 8 by canine PBMCs after stimulation with 
supernatant collected from cells infected with adenovirus Ad5/3-hTERT and Ad5/3-hTERT 
expressing human CD40L. A549 cells were infected with Ad5/3-hTERT or Ad5/3-hTERT-
CD40L, and the supernatant was collected, purified by filtering and used to stimulate canine
PBMCs. Non-infected cells were used as controls. IL-8 production was measured by ELISA at 
24, 48, 72 and 96 h after virus infection.
With the anti-caspase antibody, identifying apoptotic cells or cells going 
into apoptosis, scattered positive staining was seen within the same areas as 
with the anti-vaccinia and anti-?-galactosidase antibodies, i.e. within and 
around the necrotic areas. Both groups showed some degree of staining, 
although it was more intensive in the tumours of the virus-treated mice.
5.2.2 FUNCTIONALITY OF HUMAN CD40L IN DOGS
Canine PBMCs produced IL-8 after exposure to the supernatant collected from 
A549 cells infected with Ad5/3-hTERT-CD40L (Figure 15). Longer exposure 
increased production of IL-8. This supports our hypothesis that human CD40 
ligand can stimulate canine PMBCs and induce pronounced 
immunostimulation in dogs.
5.2.3 BIOPSY TRASDUCTION ASSAY
Transduction of vvdd-hCD40L-tdTomato was evidenced in six canine biopsy 
samples, including one canine osteosarcoma, one grade 2 mast cell tumour, 
one mammary carcinoma in a benign mixed mammary tumour (Figure 16), 
two hyperplastic splenic nodules and one ossifying epulis. In mammary 
carcinoma, transduction was detected at all time-points, whereas in 
osteosarcoma transduction was only monitored on days 2 and 4, but not on 
day 1 after infection. In the rest of biopsies, transduction was identified only 
one day after infection and not at later time-points. Transduction of tdTomato 
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Fluorescence of tdTomato confirming transduction oncolytic vaccinia virus 
infection in canine tumour biopsies. Biopsies were infected with vvdd-hCD40L-tdTomato at 5
x 106 pfu/well, and the infection was followed at 1, 2 and 4 days after infection. Grade II mast cell 
tumour at day 1 (A) and osteosarcoma (B) and mammary carcinoma at day 4 (C).
was not detected in three samples, including tubulopapillary mammary 
carcinoma and two grade 3 mast cell tumours from the same dog.
5.2.4 VACCINIA VIRUS IN A DOG MODEL (III)
The dogs enjoyed a good quality of life during the study period, and only a few 
adverse events associated with virus administration occurred.
5.2.4.1 Adverse events
Overall, the dogs did well and experienced only short-term adverse events. 
Dog 1 had grade 1 fever (39.5°C) and lethargy after the virus administration,
but no other adverse events. Dog 2 had a mild increase in rectal temperature, 
although not fulfilling grade 1 elevation. Rectal temperature of both dogs is 
shown in Figure 17.
Unexpectedly, dog 2 had a possible grade 3 seizure 5.5 h after the first virus 
administration. The incident was not evidenced by anyone, but barking was 
heard from the kennel, and dog 1 was attacking dog 2, who was situated in 
lateral recumbency on the floor when the investigator arrived less than one 
minute after the barking started. Dog 2 did not stand up immediately when 
dog 1 was moved away, although no abnormalities were found in his physical 
and neurological examination after he was picked up and carried immediately 
to an examination table.  
No other adverse events were observed. Subsequent virus doses were 
reduced to 0.8 x 108 TCID50/kg, and the dogs were monitored by video 
cameras for 24 h after each virus administration.
A grade 1 increase in ALP was detected in laboratory tests in dog 1 (Table 
16). Dog 2 had low albumin (grade 1) already in the baseline samples, and it 
decreased further during the study, but the values did not exceed grade 1. In 
addition, both dogs had low bilirubin and cholesterol already before virus 
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administration. Haematology and urinalysis showed no significant changes. 
Rectal temperature of the dogs receiving oncolytic vaccinia virus. The number 
after dog number shows the infusion number. The horizontal dashed lines highlights the upper 
and lower limit of normal rectal temperature of the study dogs.
Table 16 Clinical chemistry values of the dogs receiving oncolytic vaccinia virus.
Results outside the reference values appear in boldface.
Dog 1 Dog 2 Reference
Day* 0 1 0 7 14 21 28 value
ALP 111 373 63 89 83 83 92 33-215 U/l
ALT 43 53 64 47 43 30 30 18-77 U/l
Albumin 31.5 30.2 29.7 28 29.1 28.9 26.2 30-41 g/l
Bilirubin 1.4 1.4 2 2.8 2.7 3.7 2.9 2.5-8.5 μmol/l
Phosphate 1.41 1.12 0.97 1.06 1.16 1.21 1.21 0.93-2.25 mmol/l
Glucose 5.4 4.8 4.3 4.7 4.3 4.6 4.7 4.0-6.4 mmol/l
Potassium 4.5 4.9 4.8 4.8 5 5.4 5.5 4.2-5.4 mmol/l
Sodium 151 152 147 148 148 147 144 147-157 mmol/l
Calcium 2.49 2.47 2.56 2.56 2.73 2.73 2.67 2.3-3.0 mmol/l
Cholesterol 2.6 3.1 3.2 3.6 3.2 3.1 3.3 3.7-9.8 mmol/l
Creatinine 72 74 59 63 65 59 66 57-116 μmol/l
Protein 56 56 60 60 64 69 70 58-77 g/l
Urea 6.2 4.6 3.4 2.8 3.7 4.1 3.3 2.4-8.8 mmol/l
*From 1st virus infusion, Day 0 is baseline before virus infusion
ALP, alkaline phosphatase; ALT, alanine aminotransferase
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5.2.4.2 Detection of the virus
Viral DNA was identified in the blood of both dogs in all samples by qPCR 
(Figure 18). The highest amount of viral DNA was present in the samples
taken immediately after virus infusion. Although viral genomes decreased
quickly during the first 4 h in blood, viral DNA was still measurable one week 
later. Transduction test and plaque assay detected infectious virus only in 
samples taken immediately after virus administration, but the amount of virus 
was too low to be quantified (Figure 19).
Detectable but not quantifiable amounts of viral DNA were discovered in 
three saliva and two urinary samples, but not in faeces (Table 17). Infectious 
virus was not identified in the transduction test or in the plaque assay.
In autopsy samples, virus DNA was mainly recovered from the spleen, and 
small amounts of viral DNA were discovered in most organs of dog 1 and in 
the lungs in dog 2 (Table 18).
Vaccinia genomes in the blood of dogs receiving intravenous infusion of 
oncolytic vaccinia virus measured by qPCR. The number after dog number shows the infusion 
number.
Table 17 Positive secretion samples for vaccinia virus genomes from the dogs 
receiving intravenous infusion of oncolytic vaccinia virus measured by qPCR. Number of 
DNA copies was <100/10 μl of purified DNA in all samples. Negative samples are not shown.
Secretion Dog Time-point
Saliva 2 1 day after 2nd virus dose
1 day after 3rd virus dose
1 day after 4th virus dose
Urine 1 1 day after 1st virus dose
2 7 days after 2nd virus dose
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Vaccinia plaque on A549 cells confirming infectious virus in the blood sample 
taken immediately after intravenous administration of vvdd-hCd40L-tdTomato. The red
colour detected with the fluorescence microscope shows transduction of tdTomato (A) and lysis 
of cell monolayer detected with light microscopy (B) indicates oncolysis of cells. Sample taken 
from dog 1 after first virus dose. Scale bar = 200 μm.
Table 18 Positive secretion samples for vaccinia virus genomes from the dogs 
receiving intravenous infusion of oncolytic vaccinia virus measured by qPCR.
Dog Tissue
Copies/mg of 
genomic DNA
1 Spleen 9.9 x 105
Adrenal glands, aorta, bone and joint, epididymis, 
oesophagus, gallbladder, gingiva, heart, kidneys, 
pancreas, sciatic nerve, pituitary gland, prostate, 
salivary gland, muscle, testes, thyroid, tongue, 
trachea
< 100
2 Spleen 3.9 x 106
Lungs < 100
5.2.4.3 Neutralizing antibodies and cytokines
At baseline, no vaccinia antibodies were monitored, but they increased after 
each virus infusion. At 2 weeks, the serum dilution that was able to block >50% 
of gene expression was 1:16, while at 4 weeks a 1:4096 fold dilution was 
required (Figure 20).
Cytokines showed no obvious changes. Indeed, we were only able to detect
measurable levels of IL-2 in the baseline sample of dog 1, but no other 
cytokines. In dog 2, measurable levels of IL-2, -6 and -12p40 were detected,
but the rest were under detection limits. 
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Serum neutralizing antibodies measured by transduction inhibition in dog 2 
receiving vaccinia virus. Serum was heat inactivated, diluted and incubated with vvdd-luc, after 
which A549 cells were challenged in triplicate for the serum-virus mixture for 20 h until luciferase 
expression was measured. Values are presented as means and standard deviation.
5.2.4.4 Post-mortem examination, histology and immunohistology
No specific findings associated with virus administration emerged in the post-
mortem examination. An incidental finding was that dog 1 suffered from
aspermatogenesis.
Since vaccinia DNA was mainly found in the spleen, 
i???????????????????? ???? ????????? ???????? ???? ?-galactosidase was 
performed only in that organ. Viral antigen was detected with the anti-vaccinia 
antibody in the cytoplasm of a few macrophages in the red pulp, consistent 
with phagocytosis of the virus (Figure 21). As expected, the anti-?-
galactosidase antibody did not result in any staining since the virus cannot 
replicate in normal tissues and ?-galactosidase is expressed only after viral 
replication.
5.2.5 SEMLIKI FOREST VIRUS IN A DOG MODEL (IV)
The dogs enjoyed a good quality of life throughout the study period, and no 
adverse events were monitored.
5.2.5.1 Adverse events
The dogs showed no clinical signs of adverse events. Haematology did not 
reveal any abnormalities, and only a minor decrease in serum albumin in 
addition to incidental findings of mild hypoglycaemia and hyponatraemia 
were observed. In addition, both dogs had low serum bilirubin, protein and 
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cholesterol already at baseline. The clinical chemistry results are shown in 
Table 19.
Vaccinia virus antigen detected in the spleen of dog 1 by 
immunocytochemistry. The green colour in the cytoplasm of macrophages suggests 
phagocytosis of vaccinia virus particles in red pulp (arrows). HRP-Green, haematoxylin 
counterstain. Scale bar = 200 μm.
Table 19 Serum clinical chemistry of the Beagles receiving SFV. Results outside the 
reference values appear in boldface.
Dog 1 Dog 2
Day* 0 7 14 21 0 7 14 21 Reference value
ALP 106 103 101 96 103 111 111 107 33-215 U/l
ALAT 34 41 37 34 26 29 31 33 18-77 U/l
Albumin 30.6 34.9 32.8 29.9 26.2 27.3 27.4 26.3 30-41 g/l
Bilirubin 1.3 1.3 1.6 1.9 1.1 0.6 1.3 1.1 2.5-8.5 μmol/l
Phosphate 1.34 1.46 1.29 1.44 1.51 1.76 1.27 1.28 0.93-2.25 mmol/l
Glucose 5.2 3.5 4.2 2.9 5.7 4.7 5.1 3.6 4.0-6.4 mmol/l
Potassium 4.8 4.6 4.6 4.5 5 4.9 5.1 5.3 4.2-5.4 mmol/l
Sodium 148 148 148 147 147 148 149 144 147-157 mmol/l
Calcium 2.58 2.88 2.7 2.65 2.58 2.56 2.54 2.51 2.3-3.0 mmol/l
Cholesterol 3 3.8 3.3 3.1 2.5 2.6 2.4 2.1 3.7-9.8 mmol/l
Creatinine 58 69 67 58 57 62 61 55 57-116 μmol/l
Protein 49 57 54 48 45 50 49 45 58-77 g/l
Urea 4.3 5.2 5.3 8.9 6.1 4.6 4.4 7.4 2.4-8.8 mmol/l
*From 1st virus infusion, Day 0 is baseline before virus infusion
ALP, alkaline phosphatase; ALT, alanine aminotransferase
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5.2.5.2 Detection of the virus
Virus could not be recovered in any of the collected serum, urine or faecal 
samples. When the negative baseline faecal samples were spiked with 106 pfu
of SFV, recoveries after the freeze-thaw cycle were 6.25 x 104 pfu/0.1 g and 
3.75 x 105 pfu/ml in dogs 1 and 2, respectively, and the corresponding recovery 
proportions were 6.25% and 37.5%. With the lower recovery proportion of 
6.25%, the calculated detection limit for virus titration from faecal samples 
was 400 pfu/g.
5.2.5.3 Neutralizing antibodies
NAbs were not detected in baseline samples, but increased after virus 
administration; on day 9, the titres were 1250 and on day 21, 250 for both dogs. 
Our results thus suggest that both dogs had contracted the virus and developed
a humoral neutralizing response to the virus. 
5.2.5.4 Post-mortem examination, histology and immunohistology
No specific changes were found in the macroscopic or histological evaluation 
of the major organs and specific tissues. Virus antigen was not detected in any 
of the examined organs.
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6 DISCUSSION
6.1 ANTI-TUMOUR ACTIVITY OF ONCOLYTIC VACCINIA 
AND SEMLIKI FOREST VIRUS IN CANINE AND 
FELINE CANCER CELLS, XENOGRAFTS AND 
TUMOUR BIOPSIES (I, II, IV)
Vvdd of Western Reserve and attenuated SFV were able infect and kill all cell 
lines examined (I, II, IV). Vvdd also delayed the growth of prostatic carcinoma 
xenografts in a subcutaneous nude mouse model and was able to infect fresh 
tumour biopsies (I). However, when feline squamous cell line SCCF1 was 
growing as an intact monolayer, oncolytic efficacy of vvdd was lost (II).
The oncolytic VV has been tested in canine cancer cell lines and xenograft 
tumour models (Gentschev et al. 2009, Gentschev et al. 2010, Gentschev et al. 
2012, Patil et al. 2012, Gentschev et al. 2013) and one VV is currently being 
assessed in a clinical trial in dogs with cancer (Gentschev et al. 2013).
We started our studies with vvdd-luc because it has already been evaluated 
in murine and human cell lines (Guse et al. 2010). The other reason was that
viruses expressing tdTomato and hCD40L were constructed later (Parviainen 
et al. 2014). Vvdd-luc was used for gene transfer analysis because the 
bioluminance of virus-expressed luciferase can be quantified numerically,
allowing more exact evaluation of gene transfer. In addition, vvdd-luc was 
used as a reference virus in some other experiments.
Efficacy of transduction and oncolytic potency of viruses differed to some 
degree between cell lines, suggesting different permissiveness of cell lines to 
VV and SFV infections. At lower virus doses, vvdd-tdTomato killed more cells 
than hCD40L-expressing virus, which could be explained by slower replication 
of the virus containing more transgenes. Oncolytic efficacy of SFV in canine 
osteosarcoma cells was comparable to sensitive human or mouse cell (IV) 
(Vähä-Koskela et al. 2006, Ketola et al. 2008, Määttä et al. 2008, Heikkilä et 
al. 2010, Ruotsalainen et al. 2012, Ruotsalainen et al. 2014). Feline squamous 
cell line SCCF1 was resistant to vvdd-induced oncolysis when growing on a
monolayer, but despite this the virus was still able to infect and transduce the 
cells (II). This cell line was also the only one that was able to form cell colonies 
after vvdd infection, suggesting marked oncolytic potency of our viruses (II).
Unfortunately, tumour-specific vvdd also efficiently transduced and killed
canine non-tumourous kidney MDCK cells (I). Since MDCK is a quickly 
dividing cell line, VGF is not needed to stimulate cell division and numerous 
nucleotides are available for viral DNA synthesis without TK. Increased 
permissiveness of the cell line could also affect the results, but it is likely not 
characteristic of all kidney cells because mice or dogs in our studies (I, III) or 
in previous studies (Guse et al. 2010, Parviainen et al. 2014) did not have any 
pathological changes in kidneys.
Discussion
83
Quick replication and production of new virions is an important feature of 
oncolytic virus. Tested cell lines produced very different amounts of new 
virions, which again could be explained by cell line permissiveness for VV 
infection. Quick oncolysis could also decrease the amount of virions produced
due to the lack of virus-producing cells, but our results do not support this 
because prostatic carcinoma and kidney cells produced the highest amounts
of infectious virus but were also the most sensitive to oncolysis in the MTS test
(I).
In a subcutaneous xenograft tumour model, VV slowed the progression of 
canine prostatic carcinoma in nude mice, although the difference was only just 
statistically significant and none of the tumours regressed completely after 
virus injection (I). Vvdd-luc was chosen in that study because CD40L is 
efficient in immunodeficient mice and human CD40L is not active in mice, and 
we also wanted to evaluate VV-induced oncolysis with as little interference 
from transgenes as possible. CD40L-expressing virus should be more powerful 
in the treatment of cancer patients due to its immunostimulatory properties 
compared with vvdd-luc.
Apoptosis has been thought to be the main route of cell death in vaccinia-
infected cells (Guo et al. 2005, Greiner et al. 2006, Liskova et al. 2011), 
Recently, programmed necrosis was reported to be the primary mode of cell 
death in ovarian cancer cells (Whilding et al. 2013). This is in line with our 
results, as we detected both apoptosis and necrosis in VV-treated xenograft 
tumours (I).
Administration of vvdd did not induce any detectable adverse events in 
mice, and necropsy showed no pathological changes associated with virus 
administration, as also reported previously (Guse et al. 2010, Parviainen et al. 
2014). The virus was only found in the tumours and not in any organs,
confirming tumour specificity of the virus.
von Euler et al. (2008) showed the activity of human CD40L in dogs by 
stimulating canine PBMCs with supernatant collected from canine prostatic 
carcinoma ACE-1 cells transduced with hCD40L-expressing adenovirus. We
also confirmed the activity of hCD40L in canine PBMCs and showed increased 
levels of IL-8, suggesting monocyte activation following the protocol used in 
humans (Pesonen et al. 2012) (I). IL-8 was also measured in canine cancer 
patients treated with hCD40L gene therapy (Westberg et al. 2013).
Immortalized cell lines and xenograft tumours differ from clinical tumours 
in many ways: spontaneous tumours are more heterogenic both 
intratumourally and between individuals than transplanted tumours, cancer 
cell kinetics differ from naturally occurring tumours, tumour development is 
usually very quick in laboratory rodents compared with pets or humans,
xenograft tumours are commonly grown in immunodeficient rodents lacking 
a normal intact immune system (Vail & MacEwen 2000, Vail & Thamm 2011, 
Ranieri et al. 2013) and the tumour microenvironment is different (Julien et 
al. 2012, Williams et al. 2013). Considering these differences, we infected
biopsies of suspected canine naturally occurring tumours with our virus. We 
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did not have a diagnosis of all biopsies beforehand, and thus, benign lesions 
and hyperplastic tissues were also included. VV was able to transduce tumour 
cells and form plaques, although transduction of tdTomato was not detected 
in three malignant tumours. 
Transient transduction was detected on day 1 in hyperplastic tissue, benign 
tumours and one grade II mast cell tumour, suggesting either that the virus 
can infect the cells but is unable to replicate in the tissues or that the cells died.
Viability of naturally occurring tumour tissues in the laboratory is a problem,
and to avoid it cancer cell lines are commonly used. Production of tdTomato 
in hyperplastic and benign lesions could be due to the high proliferative rate 
of cells and an activated EGRF pathway. Rudin et al. (2003) used oncolytic 
adenovirus to treat premalignant human oral dysplasia, and therefore, the
thought of using VV in hyperplastic and benign lesions is appealing.
6.2 PRODUCTION OF VACCINIA VIRIONS IN FELINE 
SCCF1 CELLS IN THE ABSENCE OF ONCOLYSIS (II)
Although feline squamous cell carcinoma cell line SCCF1 was resistant to vvdd-
induced oncolysis when growing on an intact monolayer, the virus was able to 
replicate in the cells, but the produced virions were morphologically abnormal.
Two poxviruses, myxoma virus (MacNeill et al. 2012) and VV (Adelfinger 
et al. 2014), are the only oncolytic viruses investigated in feline cancer cell 
lines. The SCCF1 cell line used here was also used in the myxoma virus study
(MacNeill et al. 2012). In their study, SCCF1 cells were found to be more 
resistant to virus-induced oncolysis and the number of viable cells after virus 
infection was not significant relative to the control group, suggesting 
resistance to myxoma virus-induced oncolysis. Also, SCCF1 showed less 
apoptotic cells than mammary carcinoma cells. These results are partly in line 
with our findings.
Poxviruses are long-known human and animal pathogens and some of 
them are regarded as zoonotic. Sequencing of the poxvirus genome has offered 
more specific knowledge about host cell infections, virus replication and 
virulence factors of VV, but there is still a lack of information on the 
transmission cycle in nature, and the origin and reservoir of VV-inducing pox 
disease in milkers in South America remain unknown (Essbauer et al. 2010, 
Kroon et al. 2011). Recently, molecular and biological characterization has
revealed differences between isolates, indicating that multiple different strains 
are involved in outbreaks (Kroon et al. 2011).
In contrast, the life cycle of VV in the host cell is well characterized (Moss 
2006). VV produces four different types of virions: intracellular mature virus
(IMV), intracellular enveloped virus (IEV), cell-associated enveloped virus
(CEV) and extracellular enveloped virus (EEV) (Ward & Moss 2001). Since we 
wanted to emphasize the identification of different mid-stage immature 
particles, we chose to use the old nomenclature in our study. Virions remaining 
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inside the cell lack the outer envelope found in the virions released outside the 
cell. 
IMVs are stable virions that enable efficient transmission between hosts,
whereas IEVs are formed by wrapping IMV with intracellular membranes and 
facilitate the transfer of the virus to the cell surface via microtubules before 
converting to CEV (Ward & Moss 2001). CEVs utilize actin tail to move and 
infect nearby cells (Ward & Moss 2001), while EEVs, containing an additional 
host cell-derived envelope, mediate virus dissemination in the circulation
(Payne 1980). The production of different VV particles promotes efficient virus 
spread and aids escape from complement and antibodies (Vanderplasschen et 
al. 1998, Hollinshead et al. 1999, Smith et al. 2002).
Several virus-encoded proteins are involved in VV morphogenesis (Liu et 
al. 2014). One of them, viral protease I7, is essential in cleavage of VV
membrane and core components in both early and late stages of virus 
assembly and is critical for transition from immature virus with nucleoids 
(IVN) to mature virus (MV) (Ansarah-Sobrinho & Moss 2004). Lack of I7 
causes arrest of VV morphogenesis, with similar features as those observed in 
SCC1 cells infected with vvdd, i.e. formation of immature viruses (IVs) and
IVNs, but no MVs. 
Other identified virus-encoded proteins include F10, A14, A17, A11 and A6,
among others (Traktman et al. 1995, Meng et al. 2012, Unger et al. 2013, 
Maruri-Avidal et al. 2013). Defect in F10 kinase induces arrest in VV 
morphogenesis at the earliest stage of virion morphogenesis, before 
membrane crescents or IMs are formed (Traktman et al. 1995). Crescent 
membrane formation is further prevented by the repression of A14 and A17 
transmembrane proteins (Unger et al. 2013), and empty immature virion-like 
structures and masses of viroplasm are formed when the synthesis of A11 is
prevented (Maruri-Avidal et al. 2013). In addition, lack of A6 prevents 
synthesis of viral membranes and results in the accumulation of large 
viroplasm inclusions containing virion core proteins (Meng et al. 2012).
As discussed above, VV maturation and morphogenesis may be affected by 
defects in viral proteins. Our results suggest that host cells could similarly be 
impacted in virus production. The lack of MVs seems to result from an inability 
of VV particles to form the core unit from viral DNA within SCCF1 cells. 
Although the crescent can close to form IV, the viral genome DNA is not 
packed or condensed to form the core unit. The loose nucleosome threads need 
some core nucleoproteins to further condense and encapsidate. Since no MV 
was detected by electron microscope, the transition of IVN to MV was 
completely arrested in SCCF1 cells. As viral genome encodes all of the core and 
membrane proteins necessary for virion maturation, our results imply that the 
SCCF1 cell line is not expressing some of the cellular co-factor target proteins 
crucial for the virus or that they are defective. Recognizing the mechanism 
behind this phenomenon would offer valuable information regarding virus 
and cell interaction.
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6.3 SAFETY AND BIODISTRIBUTION OF ONCOLYTIC 
VACCINIA AND SEMLIKI FOREST VIRUS IN 
LABORATORY BEAGLES (III, IV)
Intravenous infusion of both VV and SFV was well tolerated, and only mild 
adverse events were monitored, with the exception of a potential unconfirmed 
seizure in dog 2 after receiving VV (III, IV). Infectious VV was detected only in 
the blood samples taken immediately after virus administration, and 
infectious SFV was not found in any of the samples. Necropsy revealed no 
changes associated with either virus, including no abnormalities in the central 
nervous system in dogs receiving SFV.
Clinical adverse events
SVF administration did not cause any clinical signs in our study dogs,
consistent with oncolytic adenovirus administered intravenously to healthy 
dogs (Smith et al. 2006) and intratumourally to tumour-bearing pet dogs 
(Laborda et al. 2014). In contrast, oncolytic VV induced mild fever and a 
possible seizure, which goes in line with the mild to moderate fever and self-
limiting nausea and vomiting reported in a dose escalation study of vesicular 
stomatitis virus (VSV) (LeBlanc et al. 2013). VV is more immunogenic than 
SFV, which could at least partly explain the lack of adverse events in dogs 
receiving SFV. In addition, VV dose was higher than SFV, but since infectious 
dose of neither of these viruses in dogs is known, comparison is difficult.
Onset of the suspected seizure in dog 2 receiving VV was not observed by 
staff (III). We found dog 2 lying on the floor in lateral recumbency and dog 1
was attacking him. The dogs had fought previously, but signs inconsistent with 
a fight included that dog 2 did not stand up immediately when dog 1 was 
removed and his limbs were extended, but not stiff, when he was picked up. 
After dose reduction, no further adverse events were monitored. We classified
the episode as a grade 3 seizure following VCOG-CTCAE guidelines 
(Veterinary cooperative oncology group 2004). VCOG-CTCAE grade 2 seizure 
is a brief generalized seizure, as in dog 2, and grade 3 is a seizure in which 
consciousness is altered. Contradictorily, in generalized epileptic seizures
dogs’ consciousness is always decreased (Platt & Olby 2004). 
Idiopathic epilepsy is common in dogs, and although no signs typical of a 
grand mal seizure, such as unconsciousness, tonic-clonic motor activity, 
drooling, urinating or defecating, were witnessed in dog 2, idiopathic epilepsy 
cannot be ruled out. About 0.1% of the dogs in the Harlan colonies have 
epileptic seizures, but dog 2 or his relatives did not have a history of epilepsy
(Stephen Hillen, Harlan Laboratories, personal communication January 
2012). 
The most likely reason for the suspected seizure is a hypersensitivity 
reaction associated with cytokine production induced by the virus or other 
components in the virus solution.  Pro-inflammatory cytokines modulate brain 
excitability and predispose to seizures, but do not usually induce seizures 
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alone, instead, they decrease the threshold for seizures from other causes
(Galic et al. 2012). TNF-??has been shown to increase neuronal excitability 
(Galic et al. 2012), but we did not find increased TNF-???????????????????????????
in dog 2. In addition, hypersensitivity reactions usually worsen in the next 
contact with the foreign antibody, but dog 2 did not have any symptoms after 
the next three virus infusions.
The risk and extent of hypersensitivity reaction are difficult to evaluate,
but the more homologous the foreign and host protein are, the less likely a
hypersensitivity reaction is (Kaneko et al. 2008). Our virus preparation 
contained 25.7 μg/ml of host cell protein and 3.4 μg/ml of bovine serum 
albumin, corresponding to 52.4 μg of foreign protein in the first dose received 
by dog 2. Human serum albumin is used to treat critically ill dogs with 
hypoalbuminaemia, and the homology between human and canine albumin is
91.7% (Kaneko et al. 2008). No severe hypersensitivity reactions or seizures 
were monitored in any of 418 dogs receiving 1 g of human albumin/kg/d 
(Vigano et al. 2010); however, type III hypersensitivity reaction was reported 
in two dogs (Powell et al. 2013). Thus, if dog 2 experienced a seizure, we think 
it was due to the high dose of immunogenic VV rather than the small amount
of human or bovine protein residues in the virus solution. 
High fever may induce seizures, especially in children, and they are 
associated with increased levels of IL-6 (Hu et al. 2014). Rectal temperature of 
dog 2 was only mildly increased, and we did not detect an increase in IL-6,
making a fever seizure highly unlikely. Another differential diagnosis for a 
seizure is collapse due to hypotensive shock or cardiovascular or respiratory 
disease, but the dog’s normal blood pressure immediately after the event, the 
lack of other clinical signs and the lack of abnormalities in necropsy do not 
support this. 
Seizures or collapses have not been monitored in any of the human patients 
treated with oncolytic VV, but fever and lethargy are reported as the most 
common adverse events (Mastrangelo et al. 1999, Park et al. 2008, Breitbach 
et al. 2011, Hwang et al. 2011, Jaime et al. 2012, Heo et al. 2013, Zeh et al. 
2015). Fever and lethargy are also common symptoms in inflammation and 
viral infections and are most likely due to an innate immune response to the
virus (Cerullo et al. 2012a, Cerullo et al. 2012b). The body temperature of dog
1 receiving VV was just at the lower limit of grade 1 fever and he also had grade 
1 lethargy (III). Dog 2 receiving VV had a mild increase in rectal temperature 
after the first virus administration, immediately after the potential seizure, but 
no lethargy (III). 
Adverse events in haematology and clinical chemistry
Haematology and differential blood count did not show any marked changes 
in any of the study dogs and was supported by histology of the bone marrow
collected at the time of necropsy (III, IV). In humans, decreases in lymphocyte, 
platelet and red blood cell counts and neutrophilia have been reported (Park 
et al. 2008, Heo et al. 2013, Zeh et al. 2015). Lack of haematological changes 
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in our dogs may be due to absence of virus replication since they did not have 
tumours.
Lymphopenia was found in healthy Beagle dogs receiving oncolytic VSV 
(LeBlanc et al. 2013), but lymphocyte count increased in 5 of 6 healthy dogs 
receiving oncolytic canine adenovirus and 3 of them had lymphocytosis (Smith 
et al. 2006). In addition, neutrophil count decreased in all dogs, but half of the 
dogs were immunosuppressed with cyclophosphamide. Viral infections are 
often associated with lymphopenia, although post-vaccinal lymphocytosis due 
to chronic immunostimulation is reported in dogs (Nelson & Couto 2009). It 
has been suggested that lymphopenia is regulated by type 1 interferons, which 
are the principal cytokines involved in viral infection, and that lymphocytes 
remain attach to the endothelium and do not migrate to tissues (Kamphuis et 
al. 2006). 
Virus detection
The copy number of the VV genome was highest in the blood samples taken 
immediately after virus infusion, quickly declining thereafter (III). In human 
cancer patients, a secondary peak of viraemia may be detected, suggestive of 
viral replication in the tumours (Park et al. 2008, Hwang et al. 2011, Heo et al. 
2013, Zeh et al. 2015). The long stability of VV genomes in the circulation of 
dogs with no tumours was not anticipated, but suggests slow clearance of viral 
genomes from the blood.
We only found infectious virus from the blood samples collected 
immediately after virus infusion (III). The amount of infectious virus was too 
low to be reliably quantified. Complement severely inhibited VV delivery in a 
recent study (Sampath et al. 2013); this may have affected our results as well,
in addition to innate immune response.
Infectious SFV was not detected in the blood of the dogs (IV), agreeing with 
an earlier VSV study (LeBlanc et al. 2013). However, since the virus was 
inactivated during the administration protocol, the detection limit for 
infectious virus may have been too low. In adult mice, attenuated SFV induces 
a transient viraemia lasting up to 4 days (Jagelman et al. 1978, Fazakerley et 
al. 1993). Susceptibility to infection and virus replication may be different 
between species and may account for the absent virus recovery in the present 
study and could also explain the differences between VV and other viruses 
tested in dogs. We did not measure viral genome copy number in the SFV 
experiment by PCR since our interest was in the risk of possible spreading of 
the virus (IV). PCR results may have offered interesting information on how 
quickly the virus clears from the circulation. Genomes of oncolytic adenovirus 
were detected in all canine blood samples until euthanasia at 4 days post-
administration (Smith et al. 2006).
At necropsy, small amounts on viral genomes were detected in multiple 
organs in dog 1 euthanized 24 h after virus infusion. In dog 2, the virus was 
mainly found in the spleen, suggesting wide spreading of the virus via 
circulation soon after virus administration and then gathering to the organ 
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consisting of immune tissue (III). Genomes of oncolytic VSV were detectable 
in the adrenal gland, kidney, spleen and testes one month after virus 
administration, and genomes of oncolytic adenovirus were mainly in the liver 
and spleen, but low numbers were detected also in other organs 4 days after 
virus administration (Smith et al. 2006).
Histopathological findings
Aspermatogenesis seen in dog 1 receiving VV (III) was the only significant 
pathological finding in our study dogs. In dogs, each spermatogenic cycle lasts 
approximately 2 weeks and spermatogenesis 2 months (Soares et al. 2009). 
Since the dog was euthanized 24 h after virus administration, 
aspermatogenesis had to be present before our study. We also discovered that 
dog 1 did not have any offspring (Stephen Hillen, Harlan Laboratories, 
personal communication January 2012) despite the fact that he was a breeding 
male.
Importantly, dogs receiving SFV had no pathological changes or cellular 
infiltrates in the central nervous system (IV). Mild CNS inflammation and 
demyelination are commonly noted in immunocompetent mice after SFV 
A7(74) infection (Suckling et al. 1978, Kelly et al. 1982). CD8+ T cells mediate 
demyelination by destruction of infected oligodendrocytes (Subak-Sharpe et 
al. 1993). Demyelination is not seen in athymic nude mice lacking T cells, but 
instead SFV A7(74) administration results in persistent infection (Jagelman et 
al. 1978). Antibodies are not associated with demyelination, although they are 
necessary to clear the infection from the brain (Fragkoudis et al. 2008). Signs 
of remyelination were observed 15 days post SFV infection (Mokhtarian et al. 
2003). Since we collected histological samples only at necropsy 21 days after 
virus administration, we may have missed mild lesions due to the ongoing 
healing process. Other possibility is that the virus never entered the CNS since 
we did not detect viraemia in our dogs.
Biosafety of viral vectors
Infectious SFV was not found in the blood of the study dogs (IV), and thus,
transmission of SFV by mosquito bites is unlikely. Neither infectious VV nor 
SFV was detected in any of the secretion samples collected, but small amounts
of VV genomes were present in a few saliva and urine samples (III). This agrees 
with the results of dogs receiving VSV, where low numbers of viral genome 
copies were detected in urine and buccal swabs up to 3 weeks after virus 
administration. Further, low viral genome numbers were detected in some 
faecal and urine samples from the dogs receiving oncolytic adenovirus (Smith 
et al. 2006). 
The dogs in our study did not have tumours to allow viral replication, and 
thus, the viral load may be higher in dogs bearing cancers. Pet dogs treated 
with oncolytic VV should not lick humans. Urine may also pose a biosafety risk 
for spreading the VV into the environment.
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In theory, recombination of the study virus with wild-type orthopoxvirus 
might occur if the cell is co-infected with both the study virus and another 
orthopoxvirus, although double-strand DNA viruses, such as VV, are usually 
stable (Brochier et al., 1996). Since the vvdd-tdTomato-hCD40L virus does not 
contain any genes increasing pathogenicity and transgenes make it more 
immunogenic, in a rare case of recombination the new virus would be less 
likely to induce infection than wild-type orthopoxviruses.  
Cytokine profile and neutralizing antibodies
We were not able to show any specific changes in cytokine levels in dogs 
receiving oncolytic VV (III). Recently, serum cytokines were measured in dogs 
receiving CD40L gene therapy (Westberg et al. 2013). Neither TNF-??nor IL-
10 was detected in the dogs, but IL-8 decreased in all but one dog after the 
treatment. In contrast, increased levels of TNF-??????-? and IL-6 have been 
found in plasma of human patients receiving intravenous infusion of oncolytic 
VV; the highest concentration was measured 8 h after virus delivery (Breitbach 
et al. 2011). In addition, IL-10 increased 4-8 days after virus delivery and IL-4
decreased transiently. The method that we used for cytokine detection has not 
been well characterized in dogs, which could partly explain our inability to 
detect cytokines.
Both VV and SFV induced high levels of NAbs (III, IV). Also healthy dogs 
receiving oncolytic VSV had detectable antibodies from day 5 (LeBlanc et al. 
2013), and dogs receiving oncolytic adenovirus had increased antibody titres 
already on day 4 (Smith et al. 2006). The results are also in agreement with 
human patients receiving oncolytic VV (Mastrangelo et al. 1999, Park et al. 
2008, Breitbach et al. 2011, Hwang et al. 2011, Jaime et al. 2012, Heo et al. 
2013, Zeh et al. 2015) and mice receiving SFV (Rodriguez-Madoz et al. 2007). 
Clinical tumour responses do not correlate with vaccinia antibody titres in 
humans (Mastrangelo et al. 1999, Park et al. 2008) so significance of anti-viral 
antibodies remains uncertain. Even if the antibodies neutralize VV, the EEV
form is not inactivated by antibodies (Sampath et al. 2013) and spread of the 
virus occurs via the circulation to metastatic lesions. 
In immunocompetent mice, IgM antibodies for SFV were detected already 
4 days after virus inoculation, peaked on day 5 and then gradually decreased 
by day 18 and disappeared (Fazakerley et al. 1993). IgG antibodies were 
detected 6 days after exposure to virus and increased still at the end of study 
on day 28 (Fazakerley et al. 1993). M???????????????????????????????6 virus 
particles (vp) intravenously had detectable NAbs 15 days after virus 
administration, whereas a smaller dose did not induce NAbs (Rodriguez-
Madoz et al. 2007). When the virus was given intratumourally at a dose of 107
or 108 vp, re-infection with 108 vp of luciferace expressing virus was only 
moderately inhibited, suggesting that SFV can be given intratumourally 
multiple times despite antibody formation. Also, antibody formation against 
SFV vector did not prevent anti-LacZ antibody development when given to 
SFV primed mice, but increased the amount of SFV virions necessary in 
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booster injections to increase serum IgG levels suggesting that SFV is not very 
immunogenic and recombinant SFV vectors can be successfully used as a 
vaccine in mice (Berglund et al. 1999). Patients with clinical disease are likely 
to have higher antibody titres than unsymptomatic individuals, although our 
dogs had very high titres after virus administration.
6.4 LIMITATIONS OF THE STUDY
We investigated the oncolytic efficacy of VV and SFV in only a few canine cell 
lines and in only one feline cell line. Including more cell lines from different 
cancer types would have yielded more information about the efficacy of the 
viruses in multiple cancer types. We could have also used other xenograft 
models in addition to the canine prostatic cancer model and more mice in each 
study to increase statistical significance. In addition, starting the treatment 
when tumours were smaller might have improved our results since the cancer 
model was quite aggressive and led to early euthanasia of the mice.
Since we aimed to treat solid tumours with VV, more biopsies and 
especially from solid tumours including soft tissue sarcomas with an activated 
EGRF factor pathway should have been included in our experiments. We did 
not evaluate the EGRF pathway at all in our studies. We could have also tried 
to quantify the amount of produced virions from the biopsy samples to 
determine whether VV can replicate in tumour tissues.
Including more dogs in our safety and biodistribution studies would have 
yielded more reliable results. From an ethical standpoint, however, we did not 
want to include more dogs since the information received from non-cancer-
bearing dogs is not comparable to dogs with tumours since the viruses 
replicate in tumour cells, and thus, the viral load is likely much higher in 
tumour-bearing dogs. The dose of VV was very high and since we planned to 
inject the virus intratumourally into pet dogs, at least the acute adverse events 
were likely to be less with a smaller intratumour dose. 
In contrast, the dose of SFV could have been higher. However, even 3-8 pfu 
of attenuated SFV strain can induce 50% protection in mice against the lethal 
SFV strain, but 20 pfu is necessary for 100% protection depending on the 
inoculation route and also the animal species (Bradish et al. 1971, Bradish & 
Allner 1972, Bradish et al. 1972). In rabbits, 20 pfu is required for 50% 
protection in addition to productive replication, although viraemia is not 
necessary (Barrett & Dimmock 1984, Kraaijeveld et al. 1984). Thus, SFV 
infection in heathy animals is self-amplifying. Indeed, we are planning to use 
the same virus dose that the study dogs received in a clinical trial, but will 
administer it intratumourally, and therefore, it is unlikely that more
pronounced viraemia will be caused even if the virus replicates in tumour 
tissue.
Discussion
92
6.5 FUTURE PLANS
We have opened a clinical trial with vvdd-hCD40L-tdTomato for dogs with 
incurable solid tumours. For SFV, more tumour cell lines, especially glioma 
cells, will be tested for oncolytic capacity of the virus and also the efficacy could 
be evaluated in tumour biopsies. If the virus proves effective, we intend to open 
a clinical trial for dogs with glioma as well.
Due to the similarity between canine and human spontaneous tumours 
(Ranieri et al., 2013, Vail and Thamm, 2011, Vail and MacEwen, 2000), the 
information yielded from the clinical trials in dogs is anticipated to also benefit 
human oncology and to reveal key safety and efficacy aspects not evident in 
rodents.
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7 CONCLUSIONS
Based on these studies, the following conclusions can be drawn:
1. Oncolytic vvdd infected and killed canine osteosarcoma (Abrams and 
D17) and prostatic carcinoma (ACE-1) cell lines, infected canine tumour 
biopsies and slowed tumour growth in nude mouse prostatic carcinoma 
(ACE-1) xenograft. Thus, oncolytic vaccine virus expressing hCD40L 
has anti-tumoural efficacy against tested canine cell lines in vitro and 
in vivo.
2. Oncolytic vvdd infected and killed feline squamous cell line SCCF1 cells,
but the killing efficacy was lost when the cells grew in an intact 
monolayer. Infectious virions were still produced, but they were
morphologically abnormal probable due to their inability to form core 
units from viral DNA and to form mature virions. Specific features of 
the cell line may be responsible for the abnormal morphology.
3. Intravenous administration of a high dose of oncolytic Western Reserve 
vaccinia virus vvdd-tdTomato-hCD40L was safe in healthy dogs despite 
the potential seizure in one dog. Infectious virus was only found in the 
blood samples taken immediately after virus infusion and not in saliva, 
urine or faeces. 
4. Attenuated SFV infected and killed tested canine osteosarcoma cell 
lines (Abrams and D17), and intravenous administration of the virus 
caused no adverse events in healthy dogs and infectious virus was not 
found in blood, urine or faeces. Based on our results, attenuated SFV 
and its derivatives are potential candidates for further studies in canine 
cancer cell lines, tumour biopsies and finally tumour-bearing dogs.
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